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The Escherichia coli (E. coli) outer membrane protease OmpT is an 
endopeptidase of the omptin family in gram negative bacteria. OmpT cleave 
preferentially between two consecutive basic residues, especially Arg-Arg, and it has 
been classified as an aspartyl protease based on its crystal structure although biochemical 
confirmation of a catalytic aspartyl residue is lacking (Vandeputte-Rutten, et al., 2001). 
Our lab has successfully engineered the P1 and P1’ specificity and selectivity of OmpT 
by employing novel strategies for the isolation of enzyme variants that cleave desired 
substrates from large combinatorial libraries screened by flow cytometry. However, the 
engineering of proteases with altered specificity beyond the P1 and P1’ residues of the 
substrate have not been demonstrated. By applying high throughput screening of large 
libraries of OmpT constructed by structure-guided saturation mutagenesis of the S2 
subsite (which recognizes the P2 residue), as well as random mutagenesis by error prone 
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PCR and DNA shuffling, we engineered an OmpT variant exhibiting about 56 fold 
change in the selectivity for the P2 position in peptide substrates.  Specifically, this 
enzyme preferred an acidic residue (Glu) over Tyr which is preferred by the wild type 
OmpT.  Molecular modeling was then employed to provide insights on how mutations 
in OmpT mediated this change in P2 specificity.   
A long term goal of protease engineering is to generate highly specific enzyme 
variants that can be used for the irreversible inactivation of disease targets. The 
anaphylatoxin C3a is a key mediator in inflammation and has been implicated with 
multiple inflammatory diseases. Since the site of anaphylatoxin C3a recognized by 
cellular receptors lie in its C-terminus, a protease cleaving the C-terminus of C3a could 
be therapeutically relevant. Using high throughput screening and directed evolution we 
successful isolated C3a cleaving enzyme variants and have characterized them 
biochemically.   
Finally as part of this dissertation we have employed high throughput screening 
methods to dissect the substrate specificity of members of the kallikrein family of 
mammalian proteases which are implicated in a number of physiological and disease 
functions.  The human tissue kallikrein (KLK) family contains 15 secreted serine 
proteases that are expressed in a wide range of tissues and have been implicated in 
different physiological functions and disease states. Of these, KLK1 has been shown to 
be involved in the regulation of multiple physiological processes such as blood pressure, 
smooth muscle contraction and vascular cell growth. KLK6 is over-expressed in breast 
and ovarian cancer tissues and has been shown to cleave peptides derived from human 
 
 ix 
myelin protein and the Aβamyloid peptide in vitro. Here we analyzed the substrate 
specificity of KLK1 and KLK6 by substrate phage-display using a random octapeptide 
library. Consistent with earlier biochemical data, KLK1 was shown to exhibit both 
trypsin-and chymotrypsin-like selectivities with Tyr/Arg preferred at the P1 site, Ser/Arg 
strongly preferred at P1’ and Phe/Leu at P2. KLK6 displayed trypsin-like activity, with 
the P1 position occupied only by Arg and a strong preference for Ser in P1’. Docking 
simulations of consensus peptide substrates was used to infer possible identities of the 
enzyme residues that are responsible for substrate binding. Bioinformatic analysis 
suggested several putative KLK6 protein substrates such as ionotropic glutamate receptor 
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Chapter 1 Protease Engineering 
 
 
1.1 Overview of Protease engineering 
 
Proteases are enzymes that cleave the peptide bond between amino acids. These 
enzymes exist in all organisms. In human proteases are predicted to account for nearly 
2% of the genome and represent 5-10% of drug targets (Overall, et al., 2007).  Proteases 
play an important role in protein activation, synthesis and degradation, and are involved 
in a wide range of physiological processes from food digestion to cell cycle progression, 
apoptosis, coagulation, wound healing, tissue remodeling, the immune reaction, etc 
(Turk, 2006).  Figure1.1 shows the nomenclature of the amino acid positions in 
substrate peptides cleaved by proteases. Based on the position of the cleavage, proteases 
are classified into exopepdidases (e.g. aminopeptidases, carboxypeptidases) and 
endopeptidases (e.g. trypsin, chymotrypsin). Based on their catalytic mechanisms and 
specifically the active site nucleophile, proteases are divided into serine, threonine, 
cysteine, aspartic, glutamic and metallopreases.  Note that glutamic proteases have not 
been found in mammals yet. Proteases can be relatively nonspecific, or very specific, for 
particular substrates. The nonspecific proteases are commonly involved in digestion or 
protein degradation, while the specific proteases are typically involved in the turning on 
cellular signals or activating enzyme cascades such as the caspases and blood clotting 









Figure1.1 Schematic representation of protease and substrate interaction; nomenclature 
of binding sites (Adapted from Turk, 2006). 
 
 
Biologists and biochemists have studied proteases extensively in order to 
understand their structures, functions, activities and substrate specificities. However, it is 
often difficult to fully understand the relationship between a protease’s structure and its 
specificity or activity. Because of the lack of detailed mechanistic models, 
reprogramming the specificity of proteases has been a challenge to protein engineers. 
Novel protease variants generated in the laboratory are often found to either display low 
catalytic rates or broad specificity relative to the corresponding wild type enzymes. In the 
early days of protease engineering, rational design based on crystal structures was 
commonly used to identify residues to be mutated. This method has obvious limitations 
due to its low throughput and the difficulty encountered in trying to predict the 
consequences of particular mutations.    
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More recently, directed evolution, has been extensively used for protease 
engineering. In direct evolution, the Darwinian principles of mutation and selection are 
mimicked in vitro. While applying selective pressure, large numbers of variants are 
screened for the desired specificity and overall level of activity. Directed evolution 
requires a functional display system compatible with the normally toxic protease.  
Combining rational design with directed evolution has proven to be a particularly 
powerful approach to engineering enzymes (Reviewed by Johannes and Zhao, 2006; 
Kaur and Sharma, 2006). Specificities of some proteases have been successfully 
engineered during the past two decades such as trypsin ((Hedstrom, et al., 1992), 
subtilisin (Ballinger, et al., 1996), aqualysin I (Tanaka, et al., 1998), HIV protease 
(O’Loughlin, et al., 2006), rat neurolysin (Kadonosono, et al., 2008), HAV 3CP 
(Sellamuthu, et al., 2008), and the E. coli OmpT (Varadarajan, et al., 2005, 2008) 
(reviewed by Pogson, et al., 2009). However most of these studies did not involve 
directed evolution. (Some of these studies will be discussed in detail in the following.)   
 
1.2 Engineering the Trypsin-Chymotrypsin-Elastase model system 
The pancreatic serine proteases trypsin, chymotrypin and elastase have been 
extensively studied as model systems for protease engineering. Trypsin, chymotrypsin 
and elastase have a high degree of structural similarity but distinct substrate specificities. 
At the P1 position, Trypsin prefers Arg/Lys; chymotrypsin favors hydrophobic residues 
Phe/Tyr/Trp; and elastase prefers Ala/Val.  Residue 189 residing at the bottom of the S1 
binding pocket was proposed to determine the specificity of P1 (reviewed by Hedstrom, 
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2002). However, redesigning the specificities of these enzymes turned out to be quite 
challenging. The single amino acid substitution of Asp189 with Ser (D189S) failed to 
generate chymotrypsin specificity (Hedstrom, et al., 1992; 1996). The chymotrypsin 
variant Ser189Asp (S189D) did not have trypsin-like activity either (Venekei, et al., 
1996). It was proposed that in addition to the S1 binding pocket, distal interactions were 
important in determining the substrate specificity and trypsin was successfully engineered 
to have chymotrypsin activity only after replacing the two loops L1 and L2 in addition to 
the D189S mutation (Hedstrom, 1992).  Moreover, the S1’ and S2’ sites of trypsin have 
been reprogrammed. The trypsin variant K60E with a single amino acid substitution 
showed about 70 fold increase in preference for Arg at P1’ than wild type trypsin (Kurth, 
et al., 1998). A trypsin variant with specificity for His at P2’ was created by introducing a 
metal binding site at the S2’ subsite (Willett, et al., 1996). Elastase has not yet been 
successfully converted to a trypsin-like protease despite extensive efforts (Venekei, et al., 
1996; Huang and Hedstrom, 1998). 
 
1.3 Engineering subtilisin 
Subtilisin has been a model enzyme for protease engineering since the 1980s. It is 
one of the best characterized of all the enzymes due to its multiple industrial applications, 
especially its use in laundry detergent. The large amount of structural and functional 
information about subtilisin made it possible to engineer its stability and specificity via 
rational design.  Plenty of variants have been generated with mutations in over 50% of 
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the 275 amino acids (reviewed by Bryan, 2000). Subtilisin has been engineered for 
increased stability, investigations of catalytic mechanism, introduction of novel activity 
and altered specificity. Successful examples of modulating specificity of the enzyme 
include: conversion of subtilisin to furilisin for cleaving tri-basic substrates (Ballinger, et 
al., 1996); altering the P1 and P1’ specificity of subtilisin by site directed mutagenesis 
and chemical modification (DeSantis, et al., 1998); altering the P2 specificity of 
aqualysin I (subtilisin related protease) with site directed mutagenesis (Tanaka, et al., 
1998); a remodeling of subtilisin specificity to cleave phosphotyrosine substrates (Knight, 
et al., 2007); a subtilisin-like yeast Golgi protease Kex2 engineered to exhibit novel P2 
specificity by genetic screening (Han, et al., 2005); and a subtilisin BPN’ variant from 
Bacillus amyloliquefaciens engineered to strongly prefer substrate with Phe or Tyr at P4 
position (Ruan, et al., 2008). 
 
1.4 Engineering specificity of HIV PR 
The human immunodeficiency virus type I protease (HIV PR) is a processing 
enzyme that cleave the HIV-1 Gag-Pol polyprotein and thus activate the proteins 
required for viral infectivity (Kohl, et al., 1988). The HIV PR is considered as cytotoxic 
non-specific protease due to its cleavage of essential proteins in E. coli, yeast and 
mammalian cells (Baum, et al., 1990; Blanco, et al., 2003). The HIV PR has been utilized 
as a model enzyme to engineer altered specificity (O’Loughlin, et al., 2006). In this 
study, HIV PR library was generated by error-prone PCR and transformed into E.coli. 
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Due to the toxicity of wild type HIV PR, screening for viable cells after induction 
eliminated the non-specific variants. Wild type HIV PR substrate sequence (decapeptide) 
was inserted into the surface loop of E.coli. β galastosidase (β-gal) and its activity is 
monitored by the decrease of β-gal activity. The isolated viable variants were further 
screened for a disrupted β-gal activity using a non-wild type preferred substrate. The 
variant P9S/I150L was isolated and exhibited novel specificity for substrate 
NRPDYLLFAE. Moreover, the variant P9S/I150L does not have the cytotoxic effect of 
the non-specific wild type. In this way, HIV PR specificity was successfully engineered 
by directed evolution (Khersonsky, et al., 2006).   
   
1.5 Engineering substrate specificity of HAV 3CP 
The human hepatitis A virus 3C protease has been utilized as a model enzyme to 
engineer substrate specificity using a genetic assay for site-specific proteolysis (GASP) in 
yeast (Sellamuthu, et al., 2008). The GASP system is shown in Figure 1.2 
The triple fusion protein included integral membrane protein, peptide substrate sequence 
for protease and the transcription factor (TF). The transcription factor LexA-b42 is 
anchored to plasma membrane due to a linker that connected to a trans-membrane 
domain. Upon the specific cleavage by protease at the linker region, the LexA-b42 was 
released from the membrane, trans-located into the cell nucleus and turned on the 
transcription of the reporter genes. Using this scheme, a four-position saturation library of 
HAV 3CP was screened for altered P2 specificity (Gln over wild type Thr). An HAV 
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3CP variant was successfully isolated demonstrating a 160-fold switch of specificity 




Figure1.2 Screening principle of GASP. (Adapted from Pogson, et. al., 2009) The triple 
fusion protein contains integral membrane protein, peptide substrate sequence for 
protease and the transcription factor (TF).  
 
1.6 Engineering E.coli OmpT 
1.6.1 Overview of E.coli OmpT 
E.coli OmpT (EC 3.4.21.87) belongs to the omptin family which consists of a 
group of highly homologous outer membrane proteases.  This protease family includes 
the E. coli OmpP, the Yersinia pepsis plasminogen activator Pla, the Salmonella enterica 
PgtE, the Shigella flexneri SopA and the Erwinia pyrifoliae PlaA (Kukkonen, et al., 
2004).  OmpT was first identified as an outer membrane protein, and then was named 
OmpT due to its low expression level at low temperature. (Rupprecht, et al., 1983)  
Mature OmpT has a molecular weight of 33.5 KD. It contains 297 amino acids and folds 
into a 10-stranded vase-shaped anti-parallel β-barrel (Vandeputte-Rutten, et al., 2001; 
Figure1.3). OmpT was first proposed to be a serine protease with Ser99 and His212 
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involved in the catalytic mechanism (Rawlings and Barrett, 1994).  However, the 
subsequent crystal structure showed this was not the case and revealed that OmpT has a 
novel proteolytic mechanism likely involving a His212-Asp210 dyad and an Asp83-
Asp85 pair to activate a putative nucleophilic water molecule. Therefore OmpT is 
tentatively classified as an aspartic protease at this point even though the details of the 
catalytic mechanism are not known at this time. Interestingly, the active site sequence and 
therefore presumably the active site structure is fully conserved in the Omptin family 
(Vandeputte-Rutten, et al., 2001). Nonetheless the assignment of OmpT as an aspartyl 







Figure1.3 Overall structure of OmpT (adapted from Vandeputte-Rutten, et al., 2001). 
The extra cellular space is at the top of the figure. There are five extracellular loop 
labeled as L1 to L5. The horizontal line indicates the boundary of outer membrane 
bilayer. The putative catalytic residues are labeled in red; the proposed LPS binding sites 
are in purple; and the aromatic residues at the boundary of hydrophobic and hydrophilic 




The full physiological function of OmpT may not be understood yet either.  So 
far, OmpT has been suggested to play a role in urinary tract infections by uropathogenic 
E. coli (Webb and Lundrigan, 1996). This was supported by the finding that OmpT 
hydrolyzes the anti-microbial peptide protamine that is secreted by the epithelial cells in 
the urinary tract (Stumpe, et al., 1997). OmpT is also considered a stress protein in E. coli 
with increased expression in response to heat shock or induction of recombinant protein 
overexpression (Gill, et al., 2000).  
Although not a biological role, OmpT has been shown to cleave recombinant 
proteins during purification such as T7 RNA polymerase, human interferon gamma and 
cyclin A (Grodberg, et al., 1988; Sugimura, et al., 1988; Yam, et al., 2001); cholesterol 
esterase/lipase fusions and the cholera toxin B subunit (Hanke, et al., 1992; Klauser, et 
al., 1992). OmpT’s putative role in E. coli pathogenesis and its potential to be a useful 
processing enzyme for recombinant fusion protein in biotechnology justifies further 
research in its enzymatic properties, mechanism of action and specificity. 
 
1.6.2 The specificity of OmpT 
The specificity of OmpT has been investigated in studies that span the last 20 
years. OmpT prefers to cleave the peptide bond between dibasic residues (Sugimura and 
Nishibara, 1988) and requires binding to lipopolysaccharide (LPS) to exhibit its catalytic 
activity (Krammer et al., 2000).  A synthetic peptide library screen revealed that OmpT 
has a strict preference for Arg (or sometimes Lys) at the P1 position but a broader 
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tolerance of Lys, Ile, His and Arg at P1’ (Dekker, et al., 2001).  OmpT exhibits minimal 
specificity at P2 as evidenced by the acceptance of the Abz fluorophore at this position.  
At P2’, OmpT has been shown to prefer Ile, Val and Ala to a certain degree.  However, 
introducing acidic residues such as Glu or Asp at either P2 or P2’ almost abolishes all 
OmpT activity, suggesting that electrostatic interactions at sites adjacent to P1 and P1’ 
might play an important role in substrate recognition (Dekker, et al., 2001).   
A phage display study refined these conclusions and further showed that OmpT 
prefers basic residues at P1 and P1’ and Val or Ala are strongly preferred at P2’. At P2, 
OmpT was found to prefer Ala, Gly, Tyr or Phe, while disfavoring acidic residues 
(McCarter, et al., 2004).  OmpT shows a lower Km rather than higher kcat for substrates 
containing basic residues at P4 and P6, and this specificity was utilized to design an 
optimal linker sequence to generate recombinant Atrial Natriuretic Peptide (ANP) that 
used OmpT as a processing enzyme (Okuno, et al., 2002).   
The crystal structure study of OmpT shows a large negatively charged groove on 
the extracellular surface, explaining its substrate specificity for consecutive positively 
charged residues and thus the cleavage of cationic peptides (Vandeputte-Rutten, et al., 
2001). The negatively charged groove is composed of 18 residues that are conserved 
within the omptin family.  Well-defined S1 and S2’ subsites are proposed according to 
the crystal structure.  In particular, Glu27 and Asp208 within the deep negative pocket 
likely form the S1 subsite.  M81 and I170 locate at the bottom of a shallow hydrophobic 
groove about 7 Å away from the negative S1 subsite.  This area might form the S2’ 
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subsite that is consistent with the high specificity for small hydrophobic residues at P2’ 
(Vandeputte-Rutten, et al., 2001).  
 
1.6.3 Engineering of OmpT 
OmpT was first engineered via directed evolution in 2000 by our previous lab 
member Mark Olsen.  A mutant of OmpT with preference for cleavage at Arg-Val was 
isolated using high throughput screening of large scale library by FACS (Olsen, et al., 
2000)  Later OmpT was successfully engineered to exhibit novel and specific substrate 
selectivity at the P1 and P1’ positions, while still maintaining high overall catalytic 
activity. (Varadarajan, et al., 2005, 2008).  
In an interesting example of how subtle recognition in a protease active site can 
be, a single mutation at 223 from Ser to Arg changed the P1 selectivity completely. While 
the wild-type OmpT prefers to cleave between Arg-Arg, the variant Ser223Arg prefers to 
cleave between Ala-Arg and shows more than three million-fold selectivity in favor of 
Ala-Arg over Arg-Arg (Varadarajan, et al., 2005).  
In the most dramatic change in an engineered protease specificity yet reported, the 
P1 specificity of OmpT was converted into a negatively charged Glu residue, a 
hydrophobic residue Tyr and a small residue Thr. All three of these residues are not 
recognized by wide-type OmpT at P1.  The P1’ specificity of OmpT has also been 
engineered to generate variants that cleave specifically between Arg-Val and Glu-Ala 
(Varadarajan, et al., 2008a). The mutation sites of OmpT variants with altered P1 
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specificity are depicted in Figure1.4. Val29, Tyr221 and Leu265 are close to the previous 
predicted negatively charged groove thought to play a role in determining the P1 
specificity. However, several distal mutations also show up in these P1 variants.  At this 
point it is not clear which of the mutations are essential for the altered specificity.  
Nevertheless, the distal mutations, if required for activity, suggest there is subsite 
cooperativity in OmpT specificity determination (Ng, et al., 2009).  
Importantly, the RV-OmpT variant exhibits higher than wild-type OmpT activity 
in plasminogen activation in vitro.  In fact, the catalytic efficiency of RV-OmpT against 
plasminogen is comparable to human tissue plasminogen activator (tPA), the clinically 
used treatment for heart attacks. In addition, human β-defensin could be recognized by 
RV-OmpT and TR2-OmpT (Varadarajan, et al., 2008a) with high efficiency.  The 
bottom line is that these studies have verified that engineered versions of OmpT can 
cleave biologically significant targets, including full-size proteins, as well as synthetic 
peptide substrates. 
OmpT was further engineered to recognize substrates that are post-translationally 
modified including sulfated tyrosine (Varadarajan, et al., 2008b). The best isolated 
variant displayed a 200-fold higher specificity for sulfotyrosine over phosphotyrosine and 
a 10-fold higher specificity for sulfotyrosine over unmodified tyrosine.  
A novel multicolor assay was established to tailor OmpT specificity for other 
post-translationally modified Tyrosine residues including 3-nitrotyrosine. Selection of the 
3-nitrotyrosine specific variant was based on the fluorescent signal of the 3-nitrotyrosine 
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containing selection substrate versus multiple counter-selection substrate signals 
containing unmodified and various other modified Tyrosine residues. The best isolated 
variant cleaved 3-nitrotyrosine efficiently, exhibiting a 3600-fold discrimination over 
sulfotyrosine, a 160-fold discrimination over unmodified , an 8000-fold discrimination  
over phosphotyrosine and an 8000-fold discrimination over phosphoserine (Varadarajan, 
















Figure1.4 The surface representation of OmpT. Glu27, Asp208 and Ser223 are shown in 
red. These red residues are suggested to compose of the S1 subsite. The two pairs of 
catalytic sites Asp83-Asp85 and His212-Asp210 are shown in yellow. Val29, Tyr221 and 
Leu265 (in orange) might also account for the P1 specificity. Other distal residues that 




Despite all of these previous successful engineering efforts using OmpT at P1 and 
P1’, the engineering of positions in the extended active site regions of OmpT has not 
been reported. In this study, we successfully isolated an engineered OmpT variant with 
altered P2 specificity.   
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1.7  Therapeutic applications of protease engineering 
1.7.1 Overview of therapeutic proteases 
Since proteases play a wide range of roles in different physiological and 
pathological processes, engineered proteases could have therapeutic application for the 
treatment of various human diseases. Until now, there have only been a few engineered 
or recombinant proteases are currently used as therapeutic agents.  These include tissue 
plasminogen activator (tPA, Tenecteplase, Retavase), activated protein C (Xigris), Factor 
VIIa (NovoSeven) and Factor IXa (Benefix, Mononine).  
Human tPA is a serine protease released by endothelial cells. tPA activates the 
inactive plasminogen into plasmin, and then plasmin, itself a protease, further degrades 
fibrin clots. Moreover, fibrin binds to tPA and plasminogen, and thus activates its own 
degradation though a positive feedback mechanism (Hoylaerts, et al., 1982).  
Recombinant tPA has been used in thrombolytic therapy of myocardial infarction, 
pulmonary embolism, peripheral vessel occlusive disease and stroke (Sarullo, et al., 
2000; Goldhaber, 2001; Schmulling, et al., 2000).  Through structure guided genetic 
engineering, variant TNK-tPA was developed that exhibits a longer elimination half-life 
than wild type tPA, increased resistance to protease inhibitors and increased fibrin 
specificity (Stewart, et al., 2000).  TNK-t-PA (TNK, tenecteplase) has been approved by 







Figure1.5 The secondary structure of tPA and TNK-tPA. (Adapted from Stewart, et al., 
2000). tPA consists of five domains: F represents a fibronectin finger-like domain; EGF 
represents a epidermal growth factor domain; K1, K2 represents two kringle domains and 
P is a protease domain. 
 
 
Figure1.5 shows a comparison of the secondary structure of tPA and TNK-tPA. 
There are five domains in tPA: a fibronectin finger-like domain (F), an epidermal growth 
factor domain (EGF), two kringle domains (K1, K2) and a protease domain (P). 
Compared to wild-type tPA, TNK tPA contains mutations N117Q (abbreviated N) and 
T103N (abbreviated T) which shift the glycosylation site in the K1 domain from 117 
upstream to 103. This change in glycosylation site accounts for the longer half-life of 
TNK-tPA. Moreover, the substitution of tetra-alanine to the KHRR (position 296 to 299, 
abbreviated K) increases the resistance of TNK-tPA to plasminogen activator inhibitor 1, 
thus strengthening its activity in vivo.  The exact reason for increased specificity of 
TNK-tPA for fibrin remains unclear (Stewart, et al., 2000). 
Another engineered tPA variant named Reteplase is also widely used as a 
thrombolytic agent in different clinical situations. Reteplase is a single chain, non-
glycosylated polypeptide containing only the K2 and P domains of tPA (presented in 
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Figure1.5) without the K1, F and EGF domains.  Reteplase displays a higher perfusion 
rate but similar thrombolytic efficacy compared to full-length recombinant tPA. This 
might be due to the long half-life of Reteplase (Simpson, et al., 2006). Moreover, 
Reteplase lacks fibrin binding so it could penetrate and activate the tissue plasminogen 
activator inside the clot, which might explain its high in vivo potency (Fisher and 
Kohnert, 1997). 
Human activated protein C (APC) plays a critical role the pathogenesis of sepsis 
and its related coagulation abnormalities. Protein C exists as an inactivate zymogen in 
circulation until it is activated by the thrombin-thrombomodulin complex (Yang, et al., 
2006). Working together with its cofactor protein S, APC degrades clotting factor V and 
VIII, thus decreases the generation of factor Xa and thrombin. In this way, APC 
attenuates the activation of coagulation cascade (Esmon, et al., 1997; Levi, et al., 2007). 
Recombinant human activated protein C (APC, Xigris) has been used to reduce the 
mortality of severe sepsis and disseminated intravascular coagulation (DIC) (Bernard, et 
al., 2001; reviewed by Levi, et al., 2007). Recombinant APC has been engineered by 
structure based approaches to exhibit better pharmacological properties. For example, 
variant L194S demonstrated higher resistance to protein C inhibitor and slower 
inactivation rate than wild type. It might be useful in patients with high level of serine 
protease inhibitors (Berg, et al., 2003).  
Neither recombinant factor VIIa (Novoseven) nor factor IXa (Benefix, Mononine) 
has been genetically engineered. However extensive research is going on to search for 
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better variants of these clotting factors. Both factor VIIa and factor IXa are vitamin K 
dependent proteases that play a key role in clotting. Novoseven could activate factor X 
directly in the extrinsic coagulation pathway without the presence of factor VIII and IX. 
Thus Novoseven is used in hemophilic patients who have the antibodies against factor 
VIII or IX and it can also be used in the management of some uncontrollable bleeding 
cases (Lloyd, et al., 2003; Franchini, et al., 2006). Recombinant factor IXa is routinely 
used to treat Hemophilia B which is factor IX deficiency (Roth, et al., 2001). Engineered 
clotting factors with enhanced specificity or pharmaceutical properties are still 
anticipated. 
The Complement system is also a protease cascade which is similar to coagulation 
system. So far there is no engineered complement interacting protease that is used in 
clinical therapy. As part of this study we tried to engineer E. coli OmpT to degrade the 
complement activation products.  
 
1.7.2 Complement system 
Therapeutic applications are typically the driving force for protease engineers. 
The present therapeutic proteases are mostly coming from the coagulation system and its 
regulatory proteases. The mammalian complement system contains a similar cascade of 
different proteases. Therefore, modulation of the complement system is an attractive 
target with many potential therapeutic applications for engineered proteases. 
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Complement is composed of a group of proteins circulating in the blood. 
Complement proteins are key components of the innate immune defenses and also link 
the innate and adaptive immune systems (Caroll, 2004; Lambris, et al., 2007). There are 
three complement activation pathways involved in the response of pathogens and other 
harmful agents: the classic, alternative and lectin pathways (Figure1.6). An antigen-
antibody complex is necessary for the activation of the classic pathway. Complement thus 
serves to link innate and adaptive immunity. In alternative pathway C3 can be 
automatically activated into C3a on microbial surface by certain microbial components 
such as bacterial lipopolysaccharide (LPS) or certain immunoglobulin such as nephritic 
factor and aggregated IgA. The lectin pathway activation is triggered by binding of lectin 
to mannose residues on the pathogen surface, which activates the MBL-associated serine 
proteases, MASP-1, and MASP-2.  Then C4 is cleaved into C4a, C4b and C2 is cleaved 
into C2a and C2b. C4b and C2a form the C3-convertase to activate the down stream 
complements, as in the classical pathway. All three pathways lead to the conversion of 
C3 to C3a and activate its downstream complement components. Ultimately, C5b and 
C6-C9 form the membrane attack complex (MAC) that leads to cell lysis (Lambris, et al., 
2007). 
Deregulation of any step in the complement cascade will inhibit or over-activate 
the complement system leading to pathological conditions. Not surprisingly, improperly 
regulated complement is involved in the pathogenesis of a wide range of diseases such as 
autoimmune diseases, ischemia/reperfusion injury and inflammatory diseases. It has been 
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stated that the development of molecules that inhibit or inactivate various complement 




Figure1.6 The complement system: classical, alternative and lectin pathway. C1-INH= 
C1 inhibitor, MAC= membrane attack complex, MASP= MBL-associated serine 
protease, MBL= mannose-binding lectin  (Adapted from www.merk.com)  
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1.7.3 Human anaphylatoxin C3a 
Anaphylatoxins are protein fragments (C3a, C4a and C5a) generated during the 
activation of the complement system (Figure1.6) from C3, C4 and C5 respectively. C3a 
and C5a binding to their receptors leads to mast cell degranulation,  an increase of 
vascular permeability, smooth muscle contraction and release of certain cytokines 
(Lambris, et al., 2005). C3a and C5a are involved in many infectious, autoimmune and 
inflammatory diseases such as sepsis, asthma, ischemia reperfusion injuries and immune 
complex diseases (reviewed by Haas and Strijp, 2007). 
As part of this study, Complement C3a was selected as a model therapeutic target 
for inactivation by engineered OmpT.  C3a is 77 amino acid peptide (Hugli, 1975), 
whose level in serum is tightly controlled by carboxypeptidase, generating an inactive 
desArg-C3a (Ember, et al., 1998). Active C3a binds to a G protein coupled receptor 
(GPCR) to effect its varied (Wetsel, et al., 2000).  In this way, C3a play an important 
role in mediating inflammatory diseases such as asthma and sepsis (Ali and Panettieri, 
2005; Drouin, et al., 2001). The active sites of C3a exist in its C-terminus. It has been 
reported that the synthetic C3a (70-77) retains only 1-2% of the activity of natural human 
C3a (Caporale, et al., 1980). The disruption of the C terminal peptides of C3a could 
interfere with its receptor binding, thus decreasing its biological activity. An enzyme 
cleaving the C-terminus of C3a specifically and efficiently might have anti-inflammatory 
effects and could have therapeutic applications for the treatment of different 
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inflammatory diseases such as asthma and sepsis (Humbles, et al., 2000; Ali and 
Panettieri, 2005).  
With extensive research studies on the complement system, numerous 
complement related drugs are under clinical or preclinical trial. However, only two drugs 
are currently available on the market including complement related protease inhibitor 
(C1-INH, Cetor/Sanquin, BerinertP/CSL, Behring, Lev Pharma) and monoclonal 
antibody to complement C5 (Eculizumab/Soliris, Alexion Pharmaceuticals). The purified 
human C1-INH is used in the treatment of hereditary angio-edema (HAE) which is 
associated with C1-INH deficiency. The Eculizumab/Soliris is marketed for the treatment 
of paroxysmal nocturnal hemoglobinuria (PNH) and is still under investigation for other 
implications (reviewed by Ricklin and Lambris, 2007). Other complement targeted drugs 
in preclinical or clinical trials include monoclonal antibodies, protein inhibitors, protein 
regulators and receptor antagonists. None of these is a protease (Ricklin and Lambris, 
2007). In this study, we are trying to engineer a protease variant that can degrade 
complement C3a. This engineered protease variant could be a novel therapeutic agent in 
the treatment of complement related diseases.  
                              
1.8 Substrate specificity investigation  
Investigation of substrate specificity plays a central role in characterization of 
engineered proteases. Substrate phage display provides a means for discerning the 
extended amino acid specificity of proteases without the need for chemical labeling 
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(Deperthes, et al., 2002; Diamond 2007). It relies on the selective cleavage of specific 
peptide sequences sandwiched between the PIII minor coat protein of filamentous phage 
and an affinity tag. The substrate specificity of over 20 bacterial and mammalian 
proteases have been analyzed by phage display (Cloutier, et al., 2002; Felber, et al., 
2005; Ferrieu-Weisbuch, et al., 2006).  
As part of this dissertation I used substrate phage to determine the specificity of 
human tissue kallikrein (KLK) 1 and 6. These two enzymes were evaluated as potential 
“scaffold proteases’ for the engineering of highly selective human peptidase that could be 
used for therapeutic purposes.  The KLK family contains 15 secreted serine proteases 
that are expressed in a wide range of tissues.  For example, KLK3, also called prostate 
specific antigen (PSA), has been the most effective marker for early detection of prostate 
cancer (www.cancer.gov).  The kallikrein family attracts a lot of attention in biomedical 
research and drug discovery.  KLK1 has been shown to be involved in the regulation of 
multiple physiological processes such as blood pressure, smooth muscle contraction and 
vascular cell growth (Bhoola, et al., 1992; Borgono, et al., 2004). The physiological 
function of KLK6 remains unclear. However, KLK6 has been shown to be over-
expressed in breast and ovarian cancer tissues. Furthermore, KLK6 been implicated in 
neurodegenerative diseases such as Alzheimer’s disease, multiple sclerosis and 
Parkinson’s disease (Bernett, et al., 2002; Iwata, et al., 2003; Magklara, et al., 2003). Due 
to the physiological significance of KLK1 and KLK6, the substrate specificities of these 
proteases have attracted much attention. As part of the study, we have successfully 
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profiled the substrate specificities of KLK1 and KLK6 by phage display. A consensus 
substrate sequence for KLK6 was identified and the identity of the endogenous protein 
substrates of KLK6 were proposed (Li, et al., 2008).  The enzyme profiles of KLK1 and 
KLK6 could provide useful information for engineering human tissue kallikreins in the 




1.9 Research outline 
In this study, chapter 2 represents the engineering of the extended specificity of 














Figure1.7 Overall scheme of engineering E. coli OmpT 
E. coli OmpT gene 
Random mutagenesis (error prone 
PCR) or site directed mutagenesis 
(saturation) 
A library of OmpT variants 
Two color sorting on FACs with 
selection and counter selection substrates 






 Variants with high signal of selection peptide 







Screening is repeated until enrichment 
is achieved 
Variants are plated; single clones are sequenced and 
checked on FACs. 
FACs 
Substrate specificity of desired variant is confirmed by Mass 




In chapter3, the engineering of OmpT to specifically cleave C3a is described. The 
C-terminal residues 67-72, His-Ala-Arg-Ala-Ser-His, are important for C3a activity, so 
we targeted the cleavage between Arg69 and Ala70 (HAR↓ASH). Although the E. coli 
outer membrane OmpT and its variants might not be used directly as therapeutic enzyme 
in humans due to likely allergic reactions in humans, a C3a-specific OmpT could 
establish a model system for engineering a complement related therapeutic protease. 
In chapter 4, the characterization of substrate specificity of Human kallikreins 1 
and 6 by phage display is described. The specificities of human serine protease kallikrein 
1 and 6 were successfully profiled by screening the substrate peptide library displayed on 
phage. The putative physiological substrates were proposed. The specificity profile of 
previously engineered OmpT variants could also be analyzed using this method in the 
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Chapter 2 Engineering Extended Protease Specificity: the S2 




Proteases, enzymes that degrade proteins or peptides, play an important role in a 
wide range of cellular processes involving protein activation and degradation. Both 
rational design and directed evolution have been used to develop proteases with altered 
specificity (reviewed by Johannes and Zhao, 2006; Kaur and Sharma, 2006; Pogson et al, 
2009). However, reprogramming extended specificity of proteases other than P1 and P1’ 
has proven to be a challenge for protein engineers with only a relatively small number of 
reported successes. Published examples include alteration of the P2 specificity of 
aqualysin I using site directed mutagenesis (Tanaka, et al., 1998) and a subtilisin-like 
yeast Golgi protease Kex2 that was engineered to exhibit novel P2 specificity through 
genetic screening (Han, et al., 2005).  In addition, Hepatitis A virus 3C protease was 
engineered to exhibit altered P2 specificity by a yeast-based transcriptional activation 
screen (Sellemuthu, et al., 2008).  In the present study we used directed evolution with 
high throughput fluorescence activated sorting to engineer the S2 subsite of the E. coli 
outer membrane protease OmpT. 
Engineering protease specificity has therapeutic implications for the treatment of 
various human diseases.  For example, recombinant tissue plasminogen activator (rt-PA) 
has been used in thrombolytic therapy of myocardial infarction, pulmonary embolism and 
stroke (Sarullo, et al., 2000; Goldhaber, 2001; Schmulling, et al., 2000).  The 
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genetically engineered and FDA approved variant TNK-t-PA exhibits increased fibrin 
specificity and a longer elimination half-life compared to wild-type t-PA. Similarly, 
recombinant human activated protein C (APC) has been used to reduce the mortality of 
severe sepsis (Bernard, et al., 2001). Specificity of APC has been engineered and variants 
exhibiting better pharmacological properties have been generated by structure-based 
mutagenesis (Berg, et al., 2003).  The general ability to dramatically alter and fine-tune 
the specificity of a protease would greatly expand the potential for using proteases as 
catalytic alternatives to therapeutic antibodies.  To be useful in a therapeutic context, 
however, it will be necessary to engineer extended specificity into a protease active site. 
In this study, the E. coli protease OmpT was used as a model to establish a high 
throughput method to fine-tune extended enzyme specificity.  OmpT is an E. coli outer 
membrane protease that belongs to the omptin family.  OmpT prefers dibasic residues in 
the P1 and P1’ positions of the substrate (Sugimura and Nishibara, 1988) and requires 
lipopolysaccharide (LPS) to exhibit its catalytic activity (Krammer et al., 2000).  Wild-
type OmpT favors small hydrophobic residues at the P2’ position of the substrate, but 
exhibits little specificity at the P2 position (Dekker, et al., 2001).  OmpT has previously 
been engineered to prefer a variety of different residues at the P1 and P1’ substrate 
positions while maintaining exquisite overall substrate specificity and high catalytic 
activity. (Varadarajan, et al., 2005, 2008).  
The OmpT crystal structure revealed a relatively well-formed S1 subsite, but the 
putative S2 subsite does not appear to be well-defined (Vandeputte-Rutten, et al., 2001).  
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Phage display analysis indicated that OmpT prefers Ala, Gly, Tyr or Phe and disfavors 
acidic residues at the P2 position (McCarter, et al., 2004).   
In the study reported here, screening of OmpT led to the isolation of variants 
preferring an acidic amino acid (Glu) at P2 while maintaining relatively high catalytic 
activity, amounting to a roughly 60-fold switch in P2 specificity compared to wild-type 
OmpT.  These results indicate that directed evolution can be successfully employed to 
engineer extended specificity distal to the scissile bond even when a binding pocket (i.e. 
subsite) appears to be poorly defined structurally.   
 
2.2 Material and methods 
2.2.1 Conjugation of FRET substrates 
The peptides Ac-CERRVGKGRGR-NH2 and Ac-KYRRVGCGRGR-NH2 were 
synthesized by GenScript (NJ, USA). BODIPY
TM
-FL-SE, Qsy7-maleimide and Qsy21-
SE were purchased from Invitrogen. Atto-633-maleimide was purchased from ATTO-
TEC (Germany). Qsy7-maleimide and BODIPY
TM
-FL-SE were conjugated to Ac-
CERRVGKGRGR-NH2 at the Cys and Lys residues, respectively, to generate FRET 
selection substrate 1. Qsy21-SE and Atto-633-maleimide were conjugated to Ac-
KYRRVGCGRGR-NH2 at the Lys and Cys residues, respectively, to generate FRET 
counter selection substrate 2 according to literature procedures (Varadarajan, et al., 




2.2.2 Library construction 
The OmpT gene used as the starting point for library generation was synthesized 
using the so-called overlapping PCR method (Stemmer, et al., 1995).  For library 
generation, the NNS (G/C) was used at chosen positions. The putative S2 region of the 
active site was identified by inspection of a substrate-OmpT model that was based on our 
previous results with P1 and P1’ engineering. The synthetic OmpT genes were assembled 
using 48 primers that were designed as previously described (Varadarajan, et al., 2009) 
with 5’ EcoRI and 3’ HindIII restriction sites surround the finished gene to facilitate 
unidirectional cloning.  PCR products corresponding to the fully assembled gene were 
gel purified, digested with EcoR1 and HindIII according to the manufacturer’s protocols, 
then ligated into a similarly digested pMLE19 vector. Ligated products were used to 
transform the E. coli MC1061 strain.  
An initial saturation library was constructed using primers with NNS codons at 
residues 29, 31, 39, 40, 263, 265, 274, 276, 280 as previously described (Varadarajan, et 
al., 2009). Following isolation of variant 3 and variant 6 (sequences in Table 2) from the 
initial saturation library, a new library was constructed using DNA shuffling of the two 
isolated clones along with wild-type OmpT. The three genes were amplified using outside 
primers 5’ CCGGGAATTCACCATGCGGGCGAAACTTCTGGGAATAGTC 3’ and 5’ 
AACAGCCAAGCTTTTAAAATGTGTACTTAAGACCAGCAGT  3’. 5 μg of PCR 
product was purified and digested using 0.2-1 unit DNase I (NEB) at room temperature 
for 9 minutes. The reaction was stopped by heating at 75
o
C for 10 minutes. The cleavage 
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products were purified by PAGE, and the 50-100 base pair bands were cut out of the gel 
and purified using Qiagen gel extraction kit. 
The isolated DNA fragments were amplified using two rounds of PCR. In the first 
round, no primers were used. The double-stranded DNA was denatured at 95
o
C 90s, 
followed by 40 cycles of denaturation at 94
o
C for 30s, annealing at 52
o
C for 45s and 
extension at 72
o
C 4 min. A final extension was performed at 72
o
C for 7 min. The second 
round of PCR was carried out using the same outside primers listed above. The DNA was 
denatured at 95
o
C for 90s, followed by 25 cycles of heating at 94
o
C 30s, annealing at 
57
o
C 30s and extension at 72
o
C 90s. The final primer extension was performed at 72
o
C 
for 10 min.  
An error-prone PCR library was constructed using the 1
st
 round DNA shuffling 
PCR product as template. The error-rate was targeted to be 0.5% by using 0.5 mM of 
Mn
2+
 in the buffer mix. The protocol was revised from previously described (Arnold 
F.H., and Georgiou G., 2003) 
In each case, library DNA was digested, ligated into plasmid pMLE19 (Varadarajan, 
et al., 2009) and transformed into E. coli strain MC1061. Copies of each library were 
stored at -80
o







2.2.3 Library screening  
The plasmid library was transformed into E.coli BL21(DE3) (F
-
 ompT hsdSB(rB-
mB-) gal dcm (DE3)) for expression and sorting. The cell suspension was prepared 
according to the procedure previously described (Varadarajan, et al., 2009). A 1 μl of 
each FRET substrate was added into 973 μl of 1% sucrose and 25 μl of cell suspension. 
The reaction was incubated at room temperature in the dark for 9 min. A 900 μl reaction 
mixed with 100 μl of 1% sucrose and analyzed on BD FACS-Aria. The sorting gate was 
set according to the fluorescence signal and about 0.5% of the cells were collected in 200 
µl 2 x YT. The collected cells were plated on LB plates 200 µg/ml and grown at 37
o
C for 
8 to 10 hours. The cells were scraped, sub-cultured and resorted. After 4-6 rounds of 
screening, plated colonies were analyzed as single colonies by FACS then analyzed by 
DNA sequencing. The screening scheme is shown in Figure 2.1 
 
2.2.4 Enzyme purification and peptide cleavage analysis 
      OmpT and its variants were purified according to published procedures (Mangel, 
et al., 1994). Purity of the enzyme was over 90% in each case as determined by SDS-
PAGE.  Peptide substrates were synthesized by solid phase synthesis (Genescript, NJ, 
US) and were >95% pure based on HPLC. The kinetic assay was carried out in 50 mM 
MES (morpholinoethanesulfonic acid), 50 μM TCEP (tris (2-carboxyethyl) phosphine 
hydrochloride) containing 10 mM EDTA (pH 6.2). 5-320 μM of substrates were 
incubated with 0.5-5 nM of purified enzyme at 37
o
C for 5 to 30 min. The reaction was 
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stopped by adding 1% TFA in 1:1 ratio and freezing in liquid nitrogen. The cleavage of 
peptides was determined by high-performance liquid chromatography (HPLC) as 
described previously (Li, et al., 2008). The reported product amounts were determined as 
peak integration areas at 280 nm and fitted to nonlinear regression of Michaelis-Menten 
equation using KaleidaGraph. 
 
2.3 Results and Discussion 
 
The presumed S1 subsite, labeled red in Figure 2.1, is well-defined in the OmpT 
crystal structure. Our previous successful attempts to engineer novel specificity at the P1 
substrate position were largely consistent with this predicted S1 location (Vandeputte-
Rutten, et al., 2001; Varadarajan, et al., 2005; 2008).  On the other hand, the S2 area of 
OmpT has not been conclusively identified.  Based on modeling with substrate and 
proximity to the presumed S1, a putative S2 area was identified and is shown as the 
circled region in Figure 2.1.  This area, comprised of residues V29, L31, V39, S40, 
T263, L265, D274, S276 and A280, lacks any well-defined features such as a cavity that 
would be expected to facilitate specific recognition.  Nevertheless, wild-type OmpT is 
known to disfavor acidic residues at P2, while favoring Ala, Gly, Tyr or Phe (McCarter, 











Figure 2.1 Molecular modeling of wild type OmpT.  Partial saturation mutagenesis was 
performed using degenerate codons (NNC/G) at putative S2 subsite shown in circled area 
in light teal including residues 29, 31, 39, 40, 263, 265, 274, 276, 280. The putative key 
residues (27, 208 and 223) of the S1 pocket are shown in red for comparison. This figure 
was produced using PyMOL (www.pymol.org).  
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In preparation for directed evolution studies, a synthetic saturation library was 
created using the overlapping PCR method with NNS codons at residues centered around 
the putative S2 site (residues 29, 31, 39, 40, 263, 265, 274, 276, 280).  A two-color 
FACS screening scheme with selection and counter selection substrates conjugated to 
different fluorophores and quenchers was used to screen the library, as shown 
schematically in Figure 2.2.  
The selection substrate (1) contained a Glu residue at the expected P2 site along 
with a BODIPY
TM
 and Qsy7 FRET pair on either side of the scissile bond.  The counter 
selection substrate (2) contained the wild-type preferred Tyr at P2 along with an Atto633 
and Qsy21 FRET pair on either side of the scissile bond.  For either substrate, OmpT 
cleavage results in significant fluorescence enhancement due to separation of the FRET 
pair. Importantly, the highly fluorescent BODIPY
TM
 and Atto633 containing cleavage 
products have a +3 overall charge, allowing for electrostatic capture on the negatively 
charged E. coli surface.  Using an isotonic sucrose solution provided for retention of 
surface bound fluorescent product at concentrations that are dependent on enzymatic 





















































































































































































































































































































































































































    FACS sort gates were set to collect cells expressing OmpT variants with high 
BODIPY
TM
 and low Atto633 fluorescence signal.  This strategy was intended to 
maximize cleavage of the Glu containing selection substrate (1), while minimizing 
cleavage of the wild-type preferred Tyr containing counter-selection substrate (2).  After 
five rounds of sorting the saturation P2 library, twenty different variants were isolated 
(sequences shown in Table 2.1).  Variant 3 and 17 have the same sequences. A near 
consensus 20 out of 21 clones contain a Val to a positively charged Arg or Lys mutation 
at position 39.  In addition, 11 out of 21 clones possess a Leu to Arg or Lys mutation at 
position 265 and 9 contain an Asp to Arg or Lys at position 274.  Taken together, the 
striking preponderance of positively charged residues in selected clones would seem to be 
consistent with selection for greater activity with the negatively charged Glu residue in 
P2. 
 
                                                                                        
Qsy7        BODIPY
TM 
 
Selection substrate 1:               Ac-CERRVGKGRGR-CONH2 
    
                                                                         
Qsy21       Atto633                                  
    







Table 2.1 Sequences of variants that were isolated from five rounds sorting of the 
saturation library. 
 
The isolated OmpT variants were analyzed as single clones with both substrates 1 
and 2.  In addition, the variants were individually purified and analyzed on HPLC using 
synthesized peptides WCYR↓RVGKGR (3) (wild type preferred) and WCER↓RVGKGR 
(4) (target specificity with a Glu residue at P2).  On these peptides, the N-terminal 
tryptophan was added as an absorbance handle for detection purposes.  Based on results 
of these initial screens (data not shown), variant 3 (V39R, D274R) and variant 6 (L31V, 
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V39K, L265V, S276K) were selected to undergo further mutagenesis.  The variants 3 
and 6 were “backcrossed” with wild-type OmpT via DNA shuffling, followed by further 
error-prone PCR to generate a library of 10
6
 different transformants.  After four rounds 
of FACS sorting with substrates 1 and 2, the mean intensity of BODIPY
TM
 fluorescence 
was increased (Figure 2.3).  Seven clones were isolated (shown in Table 2.2).  Single 
clones were cultured and analyzed on FACS as before.  The variant 25 was selected for 
further analysis because it exhibited the highest preference for the selection substrate 1 
over substrate 2 (Figure 2.4).  
The enzymatic kinetics of purified samples of wild-type OmpT and the variant 25 
were determined using an HPLC assay with peptide substrates 3 and 4 (Table 2.3).  The 
wild-type OmpT cleaved the YR↓R containing substrate (3) roughly 14-fold more 
efficiently than the ER↓R substrate (4) based on a comparison of catalytic efficiency 
(kcat/KM) values.  This wild-type specificity is largely due to differences in KM values.  
On the other hand, comparison of catalytic efficiencies (kcat/KM) for the variant 25 
revealed a roughly 4-fold preference for the ER↓R substrate (4) compared to the YR↓R 
containing substrate (3).  For the variant 25, specificity is largely the result of 
differences in KM values. It is possibly due to the positive charged mutations on putative 
S2 subsite which altered the binding of Glu or Tyr at P2 of the substrate. It is important to 
note that overall, the catalytic efficiency of the variant 25 reacting with the ER↓R 
substrate (4) was about three fold lower than that of wild type OmpT reacting with the 





























































































































































































































































































C      D 
 
 
                                                                                         
Qsy7     BODIPY
TM 
 
Selection substrate 1:                Ac-CERRVGKGRGR-CONH2 
    
                                                                         
Qsy21   Atto633                                  
    
Counterselection substrate 2:        Ac-KYRRVGCGRGR-CONH2 
 
 
Figure 2.4 FACS analysis of wild type OmpT and the variant 25.  A: wild type OmpT 
with the selection substrate 1. B: wild type OmpT with the counter selection substrate 2. 
C: The variant 25 with the selection substrate 1. D: The variant 25 with the counter 




Table 2.2 Sequences of variants that were isolated from sorting of DNA shuffling and 





Closer inspection of the data in Table 2.3 reveals that although there is an 
approximately 56-fold change in specificity between wild type OmpT and variant 25, the 
difference comes down to variant 25 having a significantly decreased ability to react with 
the YR↓R containing substrate (3) and an increase in activity with the ER↓R substrate 
(4).   Michaelis-Menten parameters of kinetics of wild type OmpT and variant 25 with 
substrate (3) and (4) are shown in Figure 2.6 and 2.7. 
The variant 25 contains four mutations: L31V, V39K, E153K and D274R (shown 
in Figure 2.5).  Among these, the L31V, V39K, and D274R mutations reside within the 
putative S2 subsite of OmpT.   The observed alteration of efficiency appears to be the 
result of both favoring ER↓R (4) and disfavoring reaction with the YR↓R containing 
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substrate (3).  Nevertheless, by the judicious choice of selection and counter-selection 
substrates along with targeted mutagenesis, we have demonstrated that dramatic changes 
in specificity at P2 can be achieved through directed evolution/high throughput screening, 
even in the case of OmpT which apparently lacks a well-defined S2 subsite.  These 
results therefore bode well for the engineering of extended specificity into the active sites 






Figure 2.5 Molecular modeling of variant 25 locations of mutations (light teal) found in 
the variant 25 is indicated on the wild type OmpT surface. This figure was produced 
using PyMOL (www.pymol.org). Note that multiple positive charged mutations on 




Table 2.3 Kinetics of wild type OmpT and isolated variant 25. . The kinetic assay was 
carried out in 50 mM MES, 50 μM TCEP containing 10 mM EDTA (pH 6.2). 5-320 μM 
of substrates were incubated with 0.5-5 nM of purified enzyme at 37
o
C for 5 to 30 min. 
 
Enzyme Peptide substrate kcat (s
-1





WT OmpT WCYR↓RVGKGR (3) 7.4± 0.2 9 ± 1 8 ± 1.2× 10
5
 
 WCER↓RVGKGR (4) 4.0 ± 0.2 70±8 6 ± 1 × 10
4
 
Variant 25 WCYR↓RVGKGR (3) 9.3± 0.4 120 ± 12 8 ± 0.9× 10
4
 










Figure 2.6: Michaelis-Menten parameters for the hydrolysis of substrate 3 
(WCYRRVGKGR) and 4 (WCERRVGKGR) by variant 25. The kinetic assay was carried 
out in 50 mM MES (morpholinoethanesulfonic acid), 50 μM TCEP (tris (2-carboxyethyl) 







Figure 2.7: Michaelis-Menten parameters for the hydrolysis of substrate 3 
(WCYRRVGKGR) and 4 (WCERRVGKGR) by wild type OmpT. The kinetic assay was 
carried out in 50 mM MES (morpholinoethanesulfonic acid), 50 μM TCEP (tris (2-
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Complement factors is a network of plasma and cell surface proteins that 
participate in the response to disease agents and play an important role in immunity and 
inflammation.  Complement factors were first discovered by Bordet in 1896 as “heat 
liable” serum component that “complements” antibodies to kill bacteria.  The 
complement system is known to be a complex network comprising more than 30 proteins 
in the blood and on cell surfaces (reviewed by Dunkelberger and Song, 2010).  It 
constitutes a principal component of the innate immune system and also links the innate 
and adaptive immune responses (Caroll, 2004; Lambris, et al., 2007). There are three 
complement activation pathways: the classic, the alternative and the lectin pathway 
(Figure1.5). The presence of antigen antibody complexes is necessary for the activation 
of the classic pathway. The alternative and lectin pathway can be spontaneously activated 
by microbial components such as bacterial surfaces. All these pathways lead to the 
conversion of C3 to C3a which in turn activates downstream processes mostly via a series 
of proteolytic cleavage reactions  Eventually, the C5b and C6-C9 proteins form the 
membrane attack complex (MAC) which leads to cell lysis (Lambris, et al., 2007).  
However, the whole picture of the function and control of the complement system is still 
under investigation.  
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The complement pathway plays an essential role in immune responses. 
Disregulation of any step in this cascade will disrupt the balance of complement 
activation and inhibition leading to pathological circumstances. Similarly, deficiency of 
components of the complement system leads to diseases. For example, deficiency of the 
complement C1 esterase inhibitor causes autosomal dominant disorder: hereditary 
angioedema (Bernstein, 2008). Another inhibitory component of the complement system, 
the decay accelerating factor (DAF, a GPI-anchored enzyme) residing on the surface of 
red blood cells protects RBCs from lysis by inadvertent complement activation on the 
RBC surface. Deficiency of DAF leads to complement mediated hemolysis and causes 
paroxysmal nocturnal hemoglobinuria (PNH) (Jonhson and Hillmen, 2002). Deficiency 
of C5 to C8 causes inability to form the MAC complex and leads to increased risk of 
Neisseria infections (Hellerud, et al., 2010).  Complement C3 deficiency is associated with 
recurrent pyogenic sinus and respiratory infection (Tedesco, et al., 1993). Moreover, deficiency 
of C3 has been shown recently to increase β-amyloid deposition and neurodegeneration in 
amyloid precursor protein (APP) transgenic mice (Maier, et al., 2008).  It is proposed that C3 
might play a beneficial role in protection from Alzheimer’s disease by clearing plaque and by 
maintaining neuronal health (Maier, et al., 2008).  Furthermore, disregulation of the 
complement system is associated with the pathogenesis of a wide range of diseases such 
as autoimmune diseases, immunodeficiency, ischemia/reperfusion injury and 
inflammatory diseases (Lambris, et al., 2007). 
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Anaphylatoxins are pro-inflammatory mediators (C3a, C4a and C5a) generated 
during the activation of complement system (Figure1.5). C3a and C5a bind to their 
receptors on  mast cells and lead to mast cell degranulation. Then, mast cells release 
inflammatory molecules such as histamine, which increases of vascular permeability and 
cause smooth muscle contraction (Lambris, et al., 2007). C3a and C5a are involved in 
different inflammatory diseases such as sepsis, asthma and ischemia-reperfusion (I/R) 
injury following stroke (reviewed by Haas and Strijp, 2007). It has been reported that C3a 
level increased in asthma patients but not in healthy individuals after allergen challenge 
(Ali and Panettieri, 2005). It has been suggested that C3a regulates the interaction 
between mast cells and airway smooth muscle cells. Therefore, it has been proposed that 
therapeutic intervention to decrease the C3a level could be useful in the treatment of 
asthma (Ali and Panettieri, 2005). 
 I/R injury is a common clinical situation in stroke. The disruption of blood flow 
causes tissue ischemia and the deprivation of oxygen causes severe tissue damage. 
However the reperfusion after ischemia elicits intense inflammatory responses causing 
further tissue damage. It has been shown that in multiple organ I/R injury triggers the 
activation of the complement system and the release of the anaphylatoxin C3a, C5a as 
well as the membrane attack complex (Arumugam et al., 2004). No effective treatment 
for I/R injury is available  
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We hypothesized that a protease that cleaves selectively C3a would be of 
therapeutic value.  Therefore, as part of this dissertation C3a was used as a model 
disease target substrate for engineered OmpT. C3a is a 77 amino acid peptide (Hugli, 
1975). In serum, the level of C3a is tightly controlled by the non-specific protease 
carboxypeptidase N which removes the C terminal Arg and generates the inactive product 
desArg-C3a (Ember, et al., 2000). After binding to its G protein coupled receptor (GPCR) 
on mast cells and basophils, C3a causes degranulation of these cells releasing the 
inflammatory molecules such as histamine, which leads to smooth muscle contraction, 
increase of vascular permeability and other inflammatory responses (Wetsel, et al., 2000).  
Thus C3a play an important role in mediating inflammatory diseases such as asthma and 
sepsis (Ali and Panettieri, 2005; Drouin, et al., 2001).  
C3a receptor binds to the C-terminus of C3a.  It has been reported that a 
synthetic C3a (70-77) peptide retains 1-2% of the activity of the natural human C3a 
(Caporale, et al., 1980). Thus, the disruption of the C-terminal active site of C3a could 
decrease its biological activity by interfering with receptor binding. (Humbles, et al., 
2000; Ali and Panettieri, 2005).  An engineered protease which specifically degrades 
C3a, could be useful in attenuating the inflammatory response in I/R injury thus minimize 
the tissue damage. Thus, the engineered C3a specific proteases could have wide 
therapeutic potentials in the treatment of shock, stroke, myocardial infarction, vascular 
diseases and trauma (Arumugam et al., 2004).  
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The complement system has been extensively investigated recent years. There are 
many complement-related drugs are under clinical or preclinical investigation.  For 
example the complement related protease inhibitor (C1-INH) is currently used in the 
treatment of hereditary angioedema (HAE) which is associated with C1-INH deficiency 
(Ricklin and Lambris, 2007). Another complement related therapeutic agent is 
Eculizumab (Solaris, Alexion Pharmaceuticals). Solaris is monoclonal antibody of 
complement protein C5 and it prevents C5 from breaking down in to C5a and C5b, thus 
prevents the activation of downstream complement cascade. It is marked for the treatment 
of paroxysmal nocturnal hemoglobinuria (PNH).   
 As part of this study, we tried to engineer a novel OmpT variant which degrades 
complement C3a specifically. Though E. coli OmpT might not be a direct therapeutic 
agent used in clinical applications, it could set up a platform for engineering of proteases 
degrading and regulating components of complement system. 
  
3.2  Material and Method 
 
3.2.1 Preparation of FRET substrates 
The peptides Ac-CHARASHKGRGR-NH2 and Ac-KYRRVGCGRGR-NH2 were 
synthesized by GenScript (Piscataway, NJ). BODIPY
TM
-FL-SE, Qsy7-maleimide and 
Qsy21-SE were purchased from Invitrogen (Carlsbad, CA). Atto-633-maleimide was 
purchased from ATTO-TEC (Siegen, Germany). Qsy7-maleimide and BODIPY
TM
-FL-
SE were conjugated to Ac-CHARASHKGRGR-NH2 at the Cys and Lys residues, 
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respectively, to generate FRET selection C3a substrate 1. Qsy21-SE and Atto-633-
maleimide were conjugated to Ac-KYRRVGCGRGR-NH2 at the Lys and Cys residues, 
respectively, to generate FRET counter selection substrate 2 according to literature 
procedures (Varadarajan, et al., 2005).  The substrate purity and identity was confirmed 
by HPLC and ESI-MS.  
                                                                                     
Qsy7        BODIPY
TM 
 
Selection C3a substrate 1:           Ac-CHARASHKGRGR-CONH2 
    
                                                                         
Qsy21       Atto633                                  
    
   Counterselection substrate 2:         Ac-KYRRVGCGRGR-CONH2 
 
 
Figure 3.1 The sequence of conjugated FRET substrates for C3a library screening and 
single clone activity assay. 
 
3.2.2 Library construction 
Preliminary results showed that the RV-OmpT variant (Varadarajan, et al., 2008) 
could hydrolyze C3a peptide at two positions both C terminal and N terminal. Therefore 
the RV-OmpT variant was subjected to random mutagenesis by error prone PCR. The 
error-rate was targeted to be 1% by using 0.5 mM of Mn
2+
 in the buffer mix. The genes 
were amplified using outside primers 5’ 
CCGGGAATTCACCATGCGGGCGAAACTTCTGGGAATAGTC 3’ and 5’ 
AACAGCCAAGCTTTTAAAATGTGTACTTAAGACCAGCAGT 3’ using described 
protocol (Chapter, Arnold F.H., and Georgiou G., 2003) 
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5’ EcoRI and 3’ HindIII restriction sites flanking the RV-OmpT gene were used for 
unidirectional cloning.  The error-prone PCR products corresponding to the full size of 
RV-OmpT gene were gel-purified using the Qiagen gel extraction kit (CA, USA), 
digested with EcoR1 and HindIII, then ligated into a similarly digested pMLE19 vector. 
Ligated products were used to transform E. coli MC1061 (F
-
 Δ(ara-leu)7697 gal E15 




) mcrA mcr B1; Casabadan and Cohen, 1980)  
and the cells were incubated in SOC at 37
o
C for 1 hr.  Subsequently the cells were 
spread on LB plates plus 1% glucose containing 200 μg/ml of ampicillin for 8 to 10 
hours. Then, the plated cells were collected and sub-cultured in LB medium with 1% 
glucose containing 200 μg/ml of ampicillin at 37
o
C either for 8 hours or overnight. The 
cells were pelleted by centrifugation and plasmid DNA was purified using the Qiagen 
miniprep kit. The plasmid DNA library was stored -80
o
C After four rounds of sorting of 
the error-prone PCR library, clones 1-8 (Table 3.1) were isolated. A secondary error-
prone PCR library was constructed using variants 1-5 as templates. The error-rate was 




3.2.3 Library screening  
The plasmid library was transformed into E.coli BL21(DE3) (F
-
 ompT hsdSB(rB-
mB-) gal dcm (DE3)) for expression and sorting. The cell suspension was prepared as 
previously described (Varadarajan, et al., 2009). A 1 μl of C3a selection substrate 1 and 
counter-selection substrate 2 was added into 973 μl of 1% sucrose and 25 μl of cell 
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suspension. The reaction was incubated at room temperature in the dark for 9 min. A 900 
μl reaction mixed with 100 μl of 1% sucrose and analyzed on FACS-Aria. The sorting 
gate was set according to the fluorescence signal and about 0.5% of the cells were 
collected in 200 µl 2 x YT. The collected cells were plated on LB plates 200 µg/ml and 
grown at 37
o
C for 8 to 10 hours. The cells were scraped, sub-cultured and resorted. After 
3-4 rounds of screening, plated colonies were analyzed as single colonies by FACS then 
analyzed by DNA sequencing. The screening scheme is the same as previously described 
in Chapter 2 (shown in Figure 2.1). 
Single colonies were inoculated in 3 ml of 2xYT medium containing 200 µg/ml of 
ampicillin.  The cells were cultured at 37
o
C for 8 to 10 hours until an OD600 
approximately 2 units.  Then 1ml of the cells was centrifuged at 10,000 rpm for 2 
minutes and resuspended in 1ml of 1% sucrose.  The centrifugation step was repeated 
and the pellet was finally resuspended in 1ml of 1% sucrose.  For activity assays, 25 µl 
of cells were labeled with 10 nM of either one FRET substrate or with both 1 and 2 and 
1% sucrose was added to make a 1 ml reaction mixture (shown in Figure 4.1). 900 µl of 
the reaction was diluted with another 100 µl of 1% sucrose. The 1ml of the reaction 
mixture was analyzed on BD FACS-Aria.    
 
3.2.4 Enzyme purification and C3a protein cleavage analysis 
      RV-OmpT and its variants were purified according to published procedures 
(Mangel, et al., 1994).  The purity of the enzyme was over 90% in each case as 
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determined by SDS-PAGE. C3a protein substrates were purchased from CALBIOCHEM 
(Darmstadt, Germany) and the purity was >98% pure based on SDS-PAGE.  For the 
C3a cleavage assay, 3 to 5 μg of C3a protein was incubated with 200 nM to 1 μM of the 
purified enzyme at 37
o
C for 2 hours to overnight. The cleavage assay was carried out in 
50 mM MES (morpholinoethanesulfonic acid), pH 6.2. , containing 10 mM EDTA. The 
reaction was stopped by adding 1% Trifluoroacetic acid (TFA) at a 1:1 ratio and was 
frozen in liquid nitrogen.  Upon thawing the reaction products were analyzed by gel 
electrophoresis on 16% SDS PAGE (Invitrogen). LC-MS peptide or protein mass 
analysis was performed by Dr. Herng-Hsiang Stony Lo in the University of Texas, 
ICMB/CRED Protein and Metabolite Analysis Facility.  An electrospray ion trap mass 
spectrometer (LCQ, ThermoFisher, San Jose, CA) coupled with a microbore HPLC 
(Magic 2002, Michrom BioResources, Auburn, CA) was used to acquire spectra of 
peptides or proteins.  Automated acquisition of full scan MS spectra was executed by 
Finnigan Excalibur™ software (ThermoFisher, San Jose, CA).  The full scan range for 
MS was 400-2000 Da.  The acquired convoluted protein spectra from LCQ were 
deconvoluted by the ProMass for Xcalibur version 2.5.0 software (Novatia LLC, 
Princeton, NJ) to afford the MH+ m/z value(s) of the protein sample.  For the peptide 
samples, zoom scans of the ions of interest were also performed to determine the charge 





3.3 Results and discussion 
In Chapter 2, we successfully engineered OmpT P2 specificity using a high-
throughput screening scheme (Figure 2.2).  In this chapter attempted to use a similar 
strategy to engineer OmpT into a specific protease for the cleavage of C3a. To determine 
the C3a cleavage sites generated by WT OmpT or RV-OmpT the reaction products  
were analyzed by LC-MS (ESI). Figure 3.10 showed the intact C3a protein with MW of 
9089.  Figure 3.11 and 3.12 showed that the major cleavage product of both WT OmpT 
and RV-OmpT were around 8284 and 824. These results confirmed the primary cleavage 
site of WT and RV-OmpT was between C terminal residue 69 and 70 (R↓A). This is 
consistent with our screening scheme. Figure 3.11A and B also showed that WT OmpT 
might have a secondary cleavage site between N-terminal residue 7 and 8 (K↓R). The 
cleavage sites on C3a were labeled with arrow in Figure 3.2. 
Based on these preliminary results, we chose the RV-OmpT as the model enzyme 
to be engineered to hydrolyze C3a specifically.  The gene for the RV-OmpT protease 
was subjected to random mutagenesis by error prone PCR with an error rate of 0.6%.  A 
library of 10
7
 transformants was obtained. 
Figure 3.1 shows the sequence of FRET substrates that were used for library 
screening. The C3a sequence 67-72 was included in the selection substrate 1. The RR and 
RV sequence which are preferred by WT OmpT and the RV-OmpT variant respectively 
were included in the counter-selection substrate 2.  
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After 4 rounds of sorting, we isolated five different variants (shown in Table 3.1). 
Variants 6-8 are exactly the same sequences as RV-OmpT. All 8 variants contain the RV 
mutation Q63R, D97H, S223D. However, we did not find consensus mutation on other 
positions. Selected single clone activity was shown in Figure 3.3 to 3.6.  Among the 
novel variants that we isolated, none of them showed significantly increase specificity for 
C3a than the parent enzyme-RV variant.  
In order to increase the specificity for C3a sequence, a secondary error PCR 
library was constructed using clone 1-5 as templates. The final library size is around 10
7 
with a 0.5% error rate estimated from sequencing results.  This 2
nd
 library was screened 
in the same way as the 1
st
 library above. After 3 rounds of sorting, clones 9 and 10 
(shown in Table 3.1) were isolated. Single clone activity on FACS is shown in Figures 
3.7 and 3.8.  As can be seen from the fluorescence histograms in Figure 3.7, clone 
showed similar activity as RV-OmpT for the C3a selection substrate 1 but lower activity 
for counter selection substrate 2. In Figure 3.8, clone10 showed decreased activity for 
both substrates.  Because of the high cost of purified C3a protein, we selected clone 9 
for a detailed analysis. WT OmpT, RV-OmpT and clone #9 proteins were purified and 
incubated with C3a at 37
o
C for 4 hour or overnight and the reaction products were by 
SDS PAGE.  As can be seen from Figure 3.9 RV-OmpT cleaved C3a protein most 
efficiently.  200nM of RV-OmpT incubated with 4 μg C3a protein for 4 hour, gave  
more than 30% cleavage of C3a was cleaved.   Unfortunately #9 showed a low cleavage 
efficiency that was similar to that of the WT OmpT. . 
72 
 
Totally we isolated 10 novel variants by directed evolution (shown in Table 3.1). 
However we could not find consensus sequence among these mutations.  Single clone of 
these variants was analyzed on FACs (Figure 3.3-3.8). Comparing to RV variant, the 
isolated clones 1-5, 9, 10 displayed relatively higher preference for selection substrate 1 
over counter-selection substrate 2. Unfortunately, our best clone #9 showed significantly 
lower efficiency in C3a protein cleavage comparing parent enzyme RV-OmpT.  It might 
be due to the structural difference between selection FRET peptide and the C3a protein. 
In the future, if we could discover novel screening system utilizing protein substrates, we 





Figure 3.2 C3a sequence (adapted from Caporale et al., 1980). The 1
st
 arrow indicated 
the primary cleavage site of both WT and RV-OmpT. The 2
nd
 arrow indicated the 











Table 3.1 Sequences of variants that were isolated from sorting of error-prone PCR 
library.   
 
Variants Mutations 
RV Q63R, D97H, S223D 
1 
Q63R, D97H, S223D, N47S, A69T, N91Y, S140G, F151L, G196S, 
A245T 
2 Q63R, D97H, S223D, E34K, G261S, S267N 
3 Q63R, D97H, S223D, T20A, T25I, N80Y, S90C, D158E 
4 Q63R, D97H, S223D, E3K, D113G 
5 Q63R, D97H, S223D, G35R 
6-8 Q63R, D97H, S223D 
9 Q63R, D97H, S223D, I16V, G161D, F192Y, S207P, H268Y 









Figure 3.3 Fluorescence histogram of single clone of RV-OmpT incubated with 10nM of 
C3a selection substrate 1 and counter-selection substrate 2.
RV-OmpT with 10nM 
C3a selection substrate 1 
RV-OmpT with 10nM C3a 







Figure 3.4 Fluorescence histogram of single clone of C3a clone1incubated with 10nM of 
C3a selection substrate 1 and counter-selection substrate 2. The fluorescence of 
hydrolysis substrate 1 is detected under FITC and substrate 2 is detected under APC. 
C3a clone1 with 10nM 
C3a selection substrate 1 
C3a clone1 with 10nM C3a 







Figure 3.5 Fluorescence histogram of single clone of C3a clone2incubated with 10nM of 
C3a selection substrate 1 and counter-selection substrate 2. 
 
C3a clone2 with 10nM 
C3a selection substrate 1 
C3a clone2 with 10nM C3a 







Figure 3.6 Fluorescence histogram of single clone of C3a clone3 incubated with 10nM of 
C3a selection substrate 1 and counter-selection substrate 2.
C3a clone3 with 10nM 
C3a selection substrate 1 
C3a clone3 with 10nM C3a 








Figure 3.7 Fluorescence histogram of single clone of C3a clone9 incubated with 10nM of 
C3a selection substrate 1 and counter-selection substrate 2. 
C3a clone9 with 10nM 
C3a selection substrate 1 
C3a clone9 with 10nM C3a 







Figure 3.8 Fluorescence histogram of single clone of C3a clone10 incubated with 10nM 




C3a clone10 with 10nM 
C3a selection substrate 1 
C3a clone10 with 10nM C3a 
counter selection substrate 2 
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C3a WT1*  WT2* C9-1  C9-2  RV1   RV2 
 
 
Figure 3.9 C3a protein cleavage assay. * 1 in the above figure indicates reaction 
incubation time as 4 hours.  *2 indicates reaction incubation time as overnight. C9 refers 
to C3a variant 9 shown in Table 3.1. In all reactions 4 μg of C3a protein incubated with 

























Figure 3.10 Mass spectrum of C3a protein. The molecular weight of C3a protein is 






















Figure 3.11A  Mass spectrum of cleavage product of C3a by WT OmpT. The major 
cleavage product is detected as 8284 which is consistent with cleavage site between C 













Major cleavage at C terminal R↓A. 
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Figure 3.11 B Mass spectrum of cleavage product of C3a by WT OmpT. The cleavage 
product is detected as 824 which is consistent with the MW of C terminal 7 amino acids. 
Another minor piece of product is detected as 804 which is consistent with MW of N 
terminal 7 amino acid.  
 
C terminal 7 amino acid of C3a 
C3a – 8283= 824 






Figure 3.12 Mass spectrum of cleavage product of C3a by RV-OmpT. The major 
cleavage product is detected as 8286 which is consistent with cleavage site between C 
terminal residue 69 and 70 (R↓A). The small piece of cleavage product is detected as 824 




Major cleavage at C terminal  
R↓A. 
The product is around 8286. 
C terminal 7 amino acid of C3a 
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The human tissue kallikrein locus contains 15 structurally similar genes. They 
represent the largest contiguous cluster of serine protease genes within the human 
genome. Human tissue kallikreins (KLKs) are expressed in a wide range of tissues and 
have been implicated in many physiological and pathological functions (Diamandis et al. 
2000; Yousef and Diamandis. 2001; Paliouras and Diamandis 2006). KLK1 was the first 
kallikrein to be discovered and was detected at high levels in human pancreas. KLK1 
together with KLK2 and KLK3 constitute the classical kallikreins. The primary 
physiological function of KLK1 is the cleavage of low molecular weight kininogen at 
Arg-Ser and Met-Lys bonds to release lysyl-bradykinin (kallidin) (Sueiras et al. 1994). 
Kallidin binding to its receptors B1 and B2 leads to a signaling cascade that regulates 
multiple physiological processes such as blood pressure, smooth muscle contraction and 
vascular cell growth, etc (Bhoola et al. 1992; Borgono et al. 2004). In addition to its 
primary function in the release of kallidin, KLK1 has also been shown to cleave 
kallistatin, somatostatin, pro-insulin, low density lipoprotein, the precursor of atrial 
natriuretic factor, prorenin, vasoactive intestinal peptide, procollagenase and 
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angiotensinogen (Bhoola et al. 1992; Yousef and Diamandis 2001). It has been suggested 
that KLK1 exhibits different physiological functions in different tissues but it is not 
known how its activity is regulated. The enzyme was shown to exhibit both trypsin- and 
chymotrypsin-like activities. Its trypsin-like activity is manifest in the cleavage of low 
molecular weight kininogen at Arg-Ser (Fiedler et al. 1979) while the chymotrypsin-like 
activity is evident in the cleavage of kallistatin (human kallikrein binding protein) and 
somatostatin, after a Phe-Phe dipeptide (Zhou et al. 1992; Pimenta et al. 1997).    
KLK6 was called zyme, protease M, neurosin or PRSS9 prior to its current 
nomenclature (Little et al. 1997; Yamashiro et al. 1997; Yousef et al. 1999). Though the 
physiological function of KLK6 is not clear, KLK6 was reported as myelencephalon-
specific protease which may involve in the regulation of myelin turnover and in 
demyelinating disease such as multiple sclerosis (Scarisbrick et al. 1997). Many proteins 
have been shown to be cleaved by KLK6 in vitro including human myelin basic protein 
(MBP), Aβ amyloid peptide, plasminogen, myelin and alpha-synuclein. Notably, KLK6 
has been implicated in neurodegenerative diseases such as Alzheimer’s, multiple sclerosis 
and Parkinson’s (Bernett et al. 2002; Iwata et al. 2003; Magklara et al. 2003). 
Furthermore, the KLK6 gene has been shown to be up-regulated in ovarian cancer and 
therefore KLK6 constitutes a potential serum biomarker for diagnosis and prognosis of 
ovarian cancer (Diamandis et al. 2003). Also, its expression is up-regulated in primary 
breast tumors and down-regulated at metastatic breast cancer sites. Since KLK6 has been 
shown to cleave extracellular matrix peptides derived from laminin and fibronectin, it 
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may be involved in tissue remodeling (Anisowicz et al. 1996; Yousef et al. 2003; Ghosh 
et al. 2004). Finally, in a recent study, Oikonomopoulou et al. reported that KLK6 cleaves 
protease-activated receptors (PARs), a family of G coupled protein receptors that are 
activated via an N-terminal cleavage proteolytic event (Oikonomopoulou et al. 2006).  
The biochemical properties and substrate specificity of KLK6 have attracted 
significant attention. Crystal structures for both proteins KLK1 and 6 are available 
(Bernett et al. 2002; Laxmikanthan et al. 2005). Even though the physiological role of 
KLK1 has been studied in detail, relatively little is known about its extended substrate 
specificity. Fluorogenic peptides derived from a preferred KLK1 substrate indicated that 
Arg, Lys. Phe, Tyr and Met are accepted in the S1 subsite, Ser is strongly preferred in S1’ 
which can also accommodate Arg to a lesser extent, and finally, Phe and Leu are 
preferred in S2 (Pimenta et al. 1999). The substrate specificity of KLK6 has been 
investigated by positional scanning using two different approaches:  Debela et al. 
employed peptide substrates of the general structure acetyl-P4-P3-P2-P1-7-
aminomethylcoumarin and reported that KLK6 exhibits strong preference for Arg or Lys 
in S2 whereas the S1 subsite accepts not only Arg but also Lys, Ala or Met (Debela et al. 
2006). These results were in conflict with the data of Angelo et al. who examined the 
substrate preference of KLK6 using the same set of fluorescence resonance energy 
transfer (FRET) peptides that had been used for the analysis of the specificity of KLK1 
mentioned above.  Specially Angelo et al. reported that only Arg is accepted in the S1 
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subsite of KLK6 whereas S2 strongly prefers Phe and, to a lesser extent Leu, over all 
other amino acids (Angelo et al. 2006).   
The determination of protease specificity using positional libraries of FRET or 
fluorogenic peptide substrates suffers from two drawbacks. First, interactions between the 
fluorescent dyes and the enzymes can bias substrate preference. This can be particularly 
true when the dye occupies the P1’ position as is the case the with 7-
aminomethylcoumarin substrates used by Debela et al. Second, positional scanning 
methods cannot take into account neighboring effects whereby the occupancy of one 
subsite by a particular amino acid affects the preference of the adjacent subsites.     
Substrate phage display provides a means for discerning the extended amino acid 
specificity of proteases without the need for chemical labeling (Deperthes 2002; Diamond 
2007). It relies on the selective cleavage of specific peptide sequences sandwiched 
between the gene pIII minor coat protein of fd bacteriophage and an affinity tag. The 
phage is immobilized on a solid support via the affinity tag and, following treatment with 
a purified protease of interest, clones containing susceptible peptide sequences are 
cleaved, which in turn releases them from the support, allowing amplification. Consensus 
substrate sequences are isolated after several rounds of panning.   The substrate 
specificity of over 20 bacterial and mammalian proteases including KLK2, KLK3 and 
KLK14 have been analyzed by substrate phage (Cloutier et al. 2002; Felber et al. 2005; 
Ferrieu-Weisbuch et al. 2006). In an effort to address discrepancies in earlier studies of 
KLK1 and KLK6 fine specificity, here we used substrate phage with a random 
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octapeptide library. Cleavage and enrichment were performed in buffers with a 
physiological pH and salt concentration. Selected peptides were synthesized, their 
respective cleavage sites were determined by MS and the kinetics of hydrolysis was 
determined. KLK1 showed its dual activity both trypsin-like and chymotrysin-like while 
KLK6 only showed trypsin-like activity with strong preference of Arg at P1 site. Both 
KLK1 and KLK6 cleaved the synthesized peptides efficiently which derived from phage 
panning sequences. Docking studies with selected peptides were employed to provide 
information on the KLK1 and KLK6 residues that form the S1 and S1’ subsites and 
interact with side chains on the substrate. 
 
4.2 Material and methods 
4.2.1 Bacterial strains, plasmids  
E. coli strain MC1061 was used for cloning (Casabadan and Cohen 1980) and 
K91BK was used for phage infection and amplification. The polyvalent phage display 
vector fUSE55 which is derived from fUSE5 was used for the construction of peptide 
libraries (Scott and Smith 1990). Unless otherwise stated, E. coli cells were grown in 
NZY medium for phage infection and propagation containing the appropriate antibiotics 
at 37
o
C in a shaking incubator. 
 
4.2.2 Protein purification  
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The mature recombinant KLK1 and KLK6 were expressed in a baculovirus/insect 
cell line system and purified as previous described (Laxmikanthan et al. 2005).   
 
4.2.3 Construction of phage library 
First, sequences encoding the FLAG tag (DYKDDDDK) and XhoI restriction site 
were inserted to the 5’ of gene gIII by ligating a synthetic DNA fragment into the SfiI site 
of fUSE55, giving rise to fUSE55-FLAG. Subsequently, the 8-mer library was 
synthesized by PCR using fUSE55-FLAG DNA (100 pg) as template, the 5’ primer, 5’-
GATAAAGGACTCGAGGCTNNKNNKNNKNNKNNKNNKNNKNNKGGGGCCGA
AACTGTTGAAAG-3’ (where N represents any nucleotide and K represents T/G), and 
the 3’ primer, 5’-CAAACGAATGGATCCTCATT AAAGCCAG-3’, followed by 
digestion with XhoI/BamHI and ligation into fUSE55-FLAG (restriction sites are  
underlined). The ligated DNA (~ 1 g) was used to transform electrocompetent E. coli 
MC1061 (~ 100 l) via electroporation. The library was sequenced to confirm the 
randomization. No bias was found within the library. 
 
4.2.4 Library screening and phage substrate purification   
10
11
 cfu (colony forming unit) of amplified substrate phage library was first 
immobilized onto 3 ml of anti-FLAG M2 Affinity Gel (Sigma, MO, US) at 4 
o
C for 4 h. 
The phage-bounded resin was washed extensively with TBS buffer (50 mM Tris-HCl, 
150 mM NaCl, pH 7.5) to remove unbound phages, then incubated with 100 to 200 nM of 
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purified enzyme in TBS buffer containing 1 mM EDTA at 37 
o
C for 45 min. The eluted 
phage particles were subsequently amplified in E. coli K91BK, purified with 
polyethylene glycol (PEG) 8000 (Sigma, MO, US) and used as input in subsequent 
rounds of screening.  From third to the last round of screening, phage clones were 
randomly selected and plasmid DNA were isolated and sequenced to determine the 
displayed substrate peptide sequences.  A total of six rounds of enrichment were 
performed for KLK1 and five rounds for KLK6.  
 
4.2.5 Western blotting   
Selected phage clones were purified and incubated with 0 - 1 µM of KLK6 or 4 
µM of KLK1 in 50 mM Tris-HCl, 150 mM NaCl buffer (pH 7.5) containing 1 mM 
EDTA at 37 
o
C for 45 min. The reaction mixture was separated with 4-20% gradient 
SDS-Polyacrylamide gel electrophoresis (PAGE) (Pierce, IL, US), and then analyzed 
with anti-FLAG antibody by western blotting.   
 
4.2.6 Kinetic measurements   
Peptides were synthesized by solid phase synthesis. (EZbiolab InC., Westfield, 
IN).  Kinetic assays were carried out in 20 mM Tris-HCl buffer, containing 1 mM 
EDTA at pH 9.0 for KLK1 and 50 mM Tris-HCl, 150 mM NaCl  containing 1 mM 
EDTA at pH 7.5 for KLK6, respectively.  1 to 200 µM of substrates were incubated 
with 0.125-100 nM of purified enzyme at 37 
o
C for 5 to 30 min. The reactions were 
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quenched by liquid nitrogen and were analyzed on a C18 reverse-phase column 
(Phenomenex, Torrance, CA) by high-performance liquid chromatography (HPLC) using 
the following gradient: 5% acetonitrile / 95% H2O for 1 min, increasing to 95% 
acetonitrile / 5% H2O for 29 min and returning to 5% acetonitrile / 95% H2O for 5 min.  
The product amount was calculated upon the integration area at 280 nm and fitted to non-
linear regression of Michaelis-Menten equation by Prism program (Graphpad, San Diego, 
CA). 
 
4.2.7 Molecular modeling 
Docking was performed using GOLD v3.1.1 (www.ccdc.cam.ac.uk) on TI-3D 
cluster with coordinates taken from human kallikrein 1 structure (PDB code 1SPJ) and 
human kallikrein 6 structure (PDB code 1L2E). For KLK 6, cavity was defined with a 
radius of 20 Å centered around the OH group of Ser195. Five peptides were tested, 
FRSA, FRSV, VRSA, VRSV, and FRFSQ, all capped with acetyl and n-methylamide 
groups. A total of 200 genetic algorithm (GA) simulations were performed on each 
peptide, with population size of 150 and 1x10
6
 operations. The following residues on 
target protein were defined with flexible side chains: His57, His99, Asp189, Ser190, 
Gln192, Ser195, Ser214, Trp215, Asn217, and Ile218, using standard rotamer libraries 
(Lovell et al. 2000). All figures were rendered in PyMOL (DeLano scientific, Palo Alto, 
CA; http://www.pymol.org). For KLK1, seven peptides were tested: FYRR, LYSR, 
ARSA, SRSA, KRSY, FYSQ, and FYSR. The following residues on the protein were 
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defined with flexible side chains: Gln41, His57, Tyr99, Asp102, Asp189, Thr190, 
Ser195, Ser214, Trp215, and Ser226. The rest of docking/GA parameters were identical 




4.3.1 Analysis of the specificity of KLK6  
We first examined whether phage encoding a putative KLK6 sequence inserted 
between the pIII protein and the FLAG peptide epitope can be recognized and cleaved 
following incubation with protease. Phages containing the octapeptide sequence 
TAFRSAYG  from  the panning and SSYISNYG which contains no putative cleavage 
sites, were constructed, purified and were incubated with 0, 0.1 or 1 µM of KLK6 at 37
o
C 
for 45min. Cleavage of the phage was then analyzed by western blotting using anti-
FLAG and anti-pIII antibody. The TAFRSAYG sequence was efficiently cleaved under 
these conditions resulting in loss of the FLAG tag. In contrast, phage encoding 
SSYISNYG remained intact (Fig. 4.1). Thus, KLK6 does not cleave pIII nor does it 
affect the integrity of the phage but can recognize substrate sequences inserted between 
pIII and the FLAG epitope. Similarly KLK1 does not cleave either pIII or the intact 






Figure 4.1 Cleavage of putative substrate phage and non-substrate phage by KLK6 by 
western blotting with anti-FLAG and anti-pIII.  Purified phage was incubated with 0 
M, 0.1 M, or 1 M of KLK6 in 50 mM Tris-HCl, 150 mM NaCl containing 1 mM 
EDTA (pH 7.5) at 37 
o
C for 45 min and analyzed by western blotting.  Phage containing 
the TAFRSAYG octapeptide is a substrate for KLK6 whereas phage containing the 
SSYISNFG sequence is not.  
 
A random octapeptide library was constructed as described earlier (Hwang et al. 
2007). The diversity of the library was 1.1x10
8
 cfus and therefore it encoded only a small 
fraction of the possible 8-mer amino acid sequences (2.56x10
10
), nonetheless it should be 
sufficient to capture the key properties of amino acids preferred by the protease (Kerr et 
al. 2005). The phage library was immobilized on anti-FLAG conjugated beads and 
subjected to panning with purified recombinant KLK1 or KLK6. Cleaved phage clones 
were amplified in E. coli K91BK and used as input in subsequent panning experiments. 
After each round of panning, phage clones were picked at random and sequenced. The 
sequencing results of KLK6-panning revealed that 6 out of 12 clones in the third round 
contained sequences encoding an Arg-Ser dipeptide sequence while 10 out of 12 clones 
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in the fourth round contained Arg-Ser dipeptide consistent with the expected cleavage of 
this sequence. Individual isolated clones from the third to the fifth round were amplified; 
phage was purified, subjected to digestion by KLK6 and the loss of the FLAG epitope 
was examined by western blotting. For comparison we also constructed phage in which 
the random octapeptide in pfUSE55 was replaced with the sequence encoding 
AAFRFSQA. This peptide had been reported to exhibit the maximum rate of cleavage by 
KLK6 in vitro (Angelo et al. 2006). Six phage clones isolated after five rounds showed a 
greater degree of cleavage relative to phage containing the AAFRFSQA peptide (Fig. 
4.2). All 20 isolated phage clones examined showed KLK6-specific cleavage. The 
selected sequences that were cleaved by KLK6 are shown in Table 4.1. Consistent with 
the expected cleavage preference of the enzyme, the sequences were aligned so that Arg 
is positioned in the P1 site.  Fig. 4.3 shows a histogram of the observed amino acid 
frequencies between the P4 to P4’ normalized relative to the codon usage in the 
respective NNK library position.  Only four different amino acids were found in the P1’ 
position with a strong preference for Ser (8-fold greater than the frequency of Ser that 
would be expected based on the NNK randomization scheme). We also observed an 
increased frequency of Val or Phe at the P2 position (4-fold and 9.6 fold, respectively) 
whereas Ala is strongly preferred at the P2’ position (9.6-fold enrichment over 
background). KLK6 appears to accept a variety of amino acids at P3, P4, P3’, and P4’ 
positions. Residues derived from the linker sequence in the octapeptide library showed up 
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at P3, P4 or P3’ and P4’ and thus do not affect the significance of the analysis described 





Figure 4.2 Cleavage of selected phage clones by KLK6.  Purified phages were 
incubated with 0 or 0.1 M  KLK6 in 50 mM Tris-HCl, 150 mM NaCl containing 1 mM 
EDTA (pH 7.5) at 37 
o
C for 45 min. The reaction mixture was separated with 4-20% 
gradient SDS-PAGE and then analyzed with anti-FLAG antibody by western blotting.  
The label + or – indicates with or without enzyme. The octapeptide sequences were 
shown above the according band. AAFRFSQA has been reported to exhibit the maximum 















































Figure 4.3. Normalized frequency of occurrence of amino acids at P1-P4 (A) and P1’-P4’ 
(B) of KLK6 substrates. The data represent the observed amino acid frequencies between 
the P4 to P4’ normalized relative to the codon usage in the respective NNK library 
position. Y-axis shows the ratio of the observed frequency to the theoretical frequency of 




Table 4.1 Alignment of sequences selected by substrate phage display with KLK6 
 
Clone P4 P3 P2 P1 P1’ P2’ P3’ P4’ 
4R-1 E A V R S A M W 
4R-11 H L V R S W N G 
5R-6 V G V R S V Y G 
5R-8 A S V R S A M Y 
4R-9 S K V R S A G A 
4R-8 Q M Y R S S W G 
Re5R-6 F G F R S V H G 
4R-22 T A F R S A Y G 
5R-17 T A F R N S L G 
5R-16 I G F R N A G A 
4R-13 S L F R M V V L 
4R-3 E A F R S S D Q 
4R-7 A S S R S V K W 
Re5R-14 A K S R S A G D 
5R-3 A F L R M A S L 
4R-17 K V L R S A T G 
4R-6 Y M T R S A M G 
4R-24 I S T R S A I W 
4R-20 W G W R Y A E T 
5R-11 K E A R S A Y G 








Amino acid sequence 









1 WYMTR↓SAMG 1.4 ±0.1  69± 7 1.9 ± 0.5 × 10
4
 
2 WIGFR↓NAGA 1.7 ± 0.7 182.6 ±87.4 1.5 ± 1.1 × 10
4
 
3 WTAFR↓SAYG 3.8 ± 1.1 336.3± 148 1.6 ± 1 × 10
4
 
4 WEAVR↓SAMW 2 ± 1.3 92.1 ± 85.1 2.2 ± 1.4 × 10
4
 
5 WEAFR↓SSDQ 1.2 ± 0.4 248.8 ± 86.4 5 ± 2.6 × 10
3
 










* WAAFRFSQA is from Ref. Angelo et al., 2006.      
 
† 
N.D. means not determined. 
 
 
Six peptides derived from selected phages were synthesized by solid-phase 
synthesis. Each peptide possessed an N-terminal Trp to facilitate detection of the intact 
peptide and the hydrolysis product by monitoring absorbance at 280 nm. Initial rates of 
hydrolysis determined by measuring product formation relative to the initial substrate 
concentration via HPLC, and the kinetic parameters kcat and Km were evaluated and fitted 
by non-linear regression to the Michaelis-Menten equation (Table 4.2). 6/7 peptides were 













. ESI-MS analysis revealed that all peptides were cleaved at a single site following the 
Arg residue. No secondary cleavage products could be detected. Even though phage 
encoding SLFRMVVL was efficiently cleaved by KLK6, the corresponding synthetic 
peptide showed very little cleavage even after four hours of incubation with 100 M 
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KLK6.  The lack of cleavage of WSLFRMVVL was at least partly due to the lower 
solubility of this peptide relative to the other sequences tested. The FLAG sequence in the 
phage encoding SLFRMVVL may have affected the solubility so that it was cleaved by 
the enzyme efficiently. 
 
4.3.2 Analysis of the specificity of KLK1   
 
Phage containing octapeptide sequences that are cleaved by KLK1 were isolated 
after six rounds of panning. Individual phage clones were amplified and examined by 
western blotting for loss of the FLAG tag following incubation with 4 µM KLK1 for 45 
minutes. 16 clones that showed extensive cleavage in this assay were examined further. 
Peptides were aligned such that either Arg or Phe and other hydrophobic amino acids 
occupied the P1 position, in accord with the published information on the substrate 
specificity of KLK1 (for a review, see Paliouras and Diamandis 2006). As expected, 
KLK1 showed both trypsin-like and chymotrypsin-like specificity (Table 4.3). 12 of 16 
phage clones encoded chymotrypsin-like substrate sequences, having large hydrophobic 
amino acids N-terminal at P1. 4 out 16 phage clones encoded trypsin-like substrates 
containing an Arg at the P1 position. The P2’ position favored polar or charged amino 
acids. No specific bias for particular amino acids could be discerned for the P2-P4 and 
P3’, P4’ positions.    
Seven peptides corresponding to selected sequences were synthesized. ESI/MS of 
the KLK1 hydolysis products revealed in all cases a single cleavage occurred N-terminal 
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to Arg or Ser, consistent with the assignment of these amino acids to the P1’ position.  
WAHRTTFYRRGA was found to be the best substrate with a kcat/Km of 1.3 ± 0.5 × 10
7
 
(Table 4.4).  
Table 4.3 Alignment of sequences selected by substrate phage display with KLK1 
(A) Chymotrypsin-like group 
Clone P4 P3 P2 P1 P1’ P2’ P3’ P4’ 
6R-29 T T F Y R R G A 
6R-28 E A S Y R R K Q 
6R-5 A S S Y R T S R 
6R-30 A A W Y R T S R 
6R-26 A R L Y S R G A 
4R-25 E A F Y S Q R F 
6R-8 T R F Y S R G R 
6R-44 S F H Y R M V G 
6R-13 G T L F R S G N 
3R-7 P N R W S T G A 
6R-11 S S E W S M P Y 
5R-18 S S Y I S N F G 
 
(B) Trypsin-like group. 
Clone P4 P3 P2 P1 P1’ P2’ P3’ P4’ 
3R-1 L E A R S A Y H 
5R-4 N A A R S T G A 
3R-13 E A K R S Y H S 
6R-27 E A S R S A T L 
Amino acids from the linker region are shown in italic. 
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1 WAHRTTFY↓RRGA 35.5 ± 1.5 3.2 ± 1.2 1.3 ± 0.5 × 107 
2 WGYARLY↓SRGA 13.1±1.8 1.6±0.5  9.4 ± 4.1 × 106 
3       WAFY↓SQRFRK 1.5 ± 0.5 0.3 ±0.1  5.6 ± 2.8 × 106 
4 WGTLF↓RSGN 9.9 ±1.3  83±17.9 1.3 ± 0.4 × 105 
5 WGTLR↓SSGN 4.2 ± 0.9 452.8± 118.3 1.1±0.5 × 104 
6 WTRFY↓SRGRG 16.5± 1 3± 1.3 7.3 ± 3.5 × 106 
7 WKLR↓SSKQ* 9.9 ± 0.5 2.3 ± 1 5.4 ±2.6 × 106 
* WKLRSSKQ is from Ref. Laxmikanthan et al., 2005. 
 
 
4.3.3 Molecular modeling of peptide substrates bound to KLK6 or KLK1 
Molecular docking of the consensus peptide substrates onto the crystal structure 
of KLK1 or KLK6 was performed using GOLD v3.1.1 For KLK 6, cavity was defined 
with a radius of 20 Å centered around the OH group of Ser195. Five acetylated peptides 
were tested (FRSA, FRSV, VRSA, VRSV, and FRFSQ) and a total of 200 genetic 
algorithm (GA) simulations were performed on each peptide. Among the top five 
candidates from the docking calculations, the Arg is shown to predominantly occupy S1 
pocket (Fig. 4.4), consistent with the biochemical data. The Arg guanidinium group is 
capable of making a number of hydrogen bonds with protein residues Asp189, Ser190, 
and Asn217 in the S1 pocket and with Ser214, Thr229, Asp102 and Tyr94 in the S2 
pocket. The catalytic Ser195 residue makes hydrogen bond contacts to the backbone of 
the peptide at P1-P1’. C-terminal residues show consistent binding to the S2’ 
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hydrophobic pocket comprising of residues Gly193, Leu40, Leu41, Gly142, Trp141, and 
Phe151. When Phe precedes Arg, as in FRSA and FRSV, the docking also predict among 
the top candidates binding modes where Phe reside in S1 and Arg in S2. This is likely an 
artifact of the scoring function of GOLD, which utilizes approximated functions 
describing hydrophobic forces.  
For KLK1, seven peptides were tested: FYRR, LYSR, ARSA, SRSA, KRSY, 
FYSQ, and FYSR. The predominant binding mode for peptides with Arg at P1 (trypsin-
like substrate) into KLK1 cavity is with Arg in S1 (Fig 4.5A). When Arg is not present at 
P1 (chymotrypsin-like substrate), Tyr is found in S1 almost exclusively, making a 
hydrogen bond with ASP189 (Fig 4.5B). For FYRR, the docking calculations show that 
either Tyr or the first Arg can occupy in the S1 pocket indicating that the benzene ring 
competes with guanidinium for the S1 pocket. As the KLK1 possess both trypsin and 







Figure 4.4 The proposed substrate binding around the active site binding pocket of 
KLK6 by docking simulation using GOLD v3.1.1. The peptide FRSA exists in the active 
site binding pocket of KLK6. Arg is capable of making hydrogen bonds with protein 














Figure 4.5 The proposed substrate binding around the active site binding pocket of 
KLK1 by docking simulation using GOLD v3.1.1. (A) The peptide ARSA (trypsin-like 
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substrate) and (B) the peptide FYSQ (chymotrypsin-like substrate) bind the active site 




In this study we investigated the substrate specificity of kallikrein 1 and 6 using 
substrate phage display. The advantages of substrate phage over methods that rely on the 
cleavage of fluorescently labeled synthetic substrate libraries have been reviewed 
recently (Sedlacek and Chen 2005). However, one potential problem with this technique 
is that clones that are cleaved by endogenous proteases either during phage biogenesis or 
upon phage purification become enriched together with sequences that are cleaved 
following incubation by the target protease. To avoid such artifacts, the cleavage of all 
isolated phage clones by either KLK1 or KLK6 as appropriate, were examined by 
western blotting following incubation with or without target protease. In this manner we 
identified a total of 16 and 20 unique sequences cleaved by KLK1 and KLK6, 
respectively. Peptides corresponding to sequences isolated by substrate phage were 
synthesized. N-terminal tryptophan was added to provide a chromophore which allowed 
the kinetics of cleavage to be determined by HPLC. The products of cleavage were 
analyzed by ESI-MS.  Synthetic peptides based on isolated sequences were found to be 
cleaved efficiently, further confirming that they constitute true substrates. Meanwhile the 
high efficiency cleavage of peptide substrates by KLK1 and KLK6 indicated that the N-
terminal tryptophan did not interfere with enzyme activity. The one exception was the 
sequence WSLFRMVVL which however was less soluble than the other synthetic 
substrates and could only be tested at lower concentrations.  
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Analysis of the sequences from the KLK6 selection revealed that the presence of 
an Arg at the P1 position of all 20 phage clones analyzed. P1’ showed a very strong 
preference for Ser although clones with Asn, Met and Tyr at that position were also 
enriched. A significant preference for Phe or Val in P2 and for Val or Ala in P2’ was also 
discerned (Table 4.1). Our results are consistent with the analysis of Angelo et al. except 
for the amino acid preferences at P2’ where positional scanning of peptide substrates did 
not detect a preference for Ala or Val. Debela et al. examined the specificity of KLK6 
using positional libraries of the general structure acetyl-P4-P3-P2-P1-ACC (ACC = 7-
amino-4-carbamoylmethylcoumarin) and reported that in addition to Arg, the S1 subsite 
can accommodate Ala, His, Met, Lys and that Arg and Lys preferentially occupy the S2 
subsite. These results are in conflict with both the data from Angelo et al. and from the 
present study and are probably a consequence of the ACC moiety occupying the P1’ 
position. It should be noted that human pro-KLK6 is self-autoactivated to an active by 
self-cleavage between Lys21 and Leu22 (Yoon et al. 2007). Self-autoactivation is 
detected after 24 hr incubation at 37 
o
C but not after 1 hr incubation at 37 
o
C indicating 
that the rate of hydrolysis is slow. In this work we carried out incubation of the phage 
with protease 30 min, to avoid the selection of slowly hydrolyzed peptides containing 
non-optimal cleavage sites. 
The tetrapetide Phe/Val-Arg-Ser-Ala/Val from P2 to P2’ constitutes the consensus 
recognition site for KLK6. A blast search (www.ncbi.nlm.nih.gov) was performed based 
on sequence homology to phage display selected substrates and the consensus sequence 
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Phe/Val-Arg-Ser-Ala/Val of KLK6. The blast search gave us hundreds of hits. However 
several putative substrate candidates of KLK6 were found based on additional 
information from published biological studies. For example, ionotropic glutamate 
receptor (GluR) has been proposed to be possible substrate of KLK6 so that KLK6 may 
be involved in the modulation of glutamate-mediated neuronal activity in CNS. (Angelo 
et al. 2006). Our blast search showed that GluR N-methyl D-aspartate 2C (GRIN2C) 
contains the sequence VRSV that matches the consensus. Similarly, GluR N-methyl D-
aspartate 2D (GRIN2D) contains the consensus sequence VRSA. This finding further 
supports the notion that the inonotropic glutamate receptor is a potential target of KLK6 
and might interact with GRIN mediating further GluR excitation in CNS.   
The major character of Parkinson syndrome is the aggregation of insoluble alpha 
synuclein and the formation of Lewy bodies in the patients’ brain (Spillantini et al. 1997). 
KLK6 was shown to degrade alpha synuclein and prevent its polymerization (Iwata et al. 
2003). We found that the synuclein alpha binding protein-synphilin contains the sequence 
FRSI which exhibits strong homology to the consensus cleavage motif determined here. 
Synphilin has been shown to interact with alpha synuclein, promote aggregation of 
synuclein and the formation of inclusion bodies in neurons (Engelender et al. 1999). Our 
results suggest that KLK6 might play a role in the degradation of synphilin thus 
decreasing the formation of inclusions in neurons in parkinson’s disease. However, 
further experiments to check the KLK6 digestion of these proteins will be suggested to 
confirm these results. 
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In addition to kininogen, KLK1 appears to have many other physiological protein 
substrates including pro-insulin, prorenin and low density lipoprotein etc (for a review, 
see Yousef and Diamandis 2002; Paliouras and Diamandis 2006). Therefore KLK1 has 
been proposed to exhibit different enzyme functions in specific tissues or cell types. 
KLK1 cleaves human low molecular weight kininogen at Met-Lys and Arg-Ser bonds 
(Sueiras et al. 1994) while it can also cleave after the Phe-Phe pair of kallistatin (Zhou et 
al. 1992) and somatostatin (Pimenta et al. 1997). Here, phage display confirmed that 
KLK1 is able to accept two distinct classes of substrates and exhibits trypsin-like and 
chymotrypsin-like activities (Table 4.3A and 4.3B). For the latter class of substrates, Tyr 
was the predominant residue in the P1 position. Further, our analysis indicates a strict 
preference for Ser or Arg in the P1’ position of chymotrypsin-like substrates of KLK1 
(Table 4.3A).   As expected based on the known substrates of KLK1 a variety of amino 
acids can be accommodated in the P2 position of the substrate, although there is a 
preference for aromatic residues (5 out of 12 phage clones).   
Substrates containing trypsin-like sites were enriched at a lower frequency 
relative to chymotrypsin-like substrates (Table 4.3B). Among the four such sequences 
obtained there was a perfect consensus for Arg at P1 and Ser at P1’. Table 4.3B also 
indicates a preference for Ala in the P3 position (3/4 sequences). However, given the 




Five peptides corresponding to sequences isolated by substrate phage were 
synthesized, the kinetics of cleavage determined by HPLC and the products of cleavage 
were analyzed by ESI-MS. All five peptides were cleaved with high catalytic efficiency 






). The best substrate was 
WAHRTTFYRRGA which was hydrolyzed very rapidly, with kcat/Km of 1.3 ± 0.5 × 10
7
 
(Table 4.4).  Interestingly, the higher rate of cleavage of this peptide was primarily due 
to an increased kcat. Although, peptide #4 (WGTLFRSGN) contained both a putative 
chymotrypsin cleavage site (between Phe and Arg) and a trypsin cleavage site (between 
Arg and Ser) incubation with KLK1 resulted exclusively in the formation of WGTLF and 
RSGN.  To examine whether the amino acids distal to the cleavage site determine 
whether KLK1 exhibits trypsin-like or chymotrypsin like activity, we synthesized a 
derivative of the substrate phage-derived peptide #4 (WGTLF↓RSGN) in which the P1 
and P1’ were changed from  Phe-Arg to Arg-Ser, respectively. This substitution resulted 
in a 10-fold reduction in the kcat/Km .  Keeping the P2-P2’ sequence in peptide #5 fixed 
but changing the P3-P4 and P3’P4’ residues increased the catalytic rate with peptide #7 
by 500 fold. 
Superposition of KLK1 and KLK6 reveals the two enzymes are very similar 
structurally, with RMSD of 0.88 Å for Cα. A closer examination shows that S1 cavity in 
KLK6 is generally tighter and is surrounded by more polar groups. Specifically, Tyr288, 
Tyr172, Thr190, Gln192, Asn217, Ile218, Gly226, and Ile138 form the S1 cavity of 
KLK6 compared to Ala228, His172, Ser190, Val192, Try217, Val218, Ser226, and 
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Ala138 in KLK1. Also, loop 216-226 is brought closer to the S1 cavity in KLK6. The 
presence of Asp189 in both KLK1 and KLK6 indicates that, unlike chymotrypsin, KLK1 
enzyme employs more subtle differences around the S1 cavity to allow for chymotrypsin-
like activity, namely a larger cavity and smaller hydrophobic groups to accommodate 
binding of aromatic groups. The docking simulations show that Arg or Tyr fit into the S1 
pocket of KLK1 equally well, which places the peptide in the binding mode consistent 
with the dual specificities of the enzyme. A major factor in determining the binding mode 
of KLK1 appears to be the residues at P1’ and P2’, as S1’ site accepts small polar 
residues and S2’ prefers large hydrophobic residues almost exclusively. The S2 site, 
according to GOLD, appears to be largely promiscuous, capable of accepting a range of 
polar and aromatic residues. For KLK6, the above preferences are also true; however, 
since the S1 pocket of KLK6 is less tolerant to large aromatic residues, GOLD predicts 
that Arg binds to S1 pocket of KLK6, facilitating trypsin-like reaction. Comparing 
different binding modes we observe that the peptide backbone stays close to catalytic 
Ser195, indicating that a nucleophilic attack is likely to take place between P1-P1’. 
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